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SUPERIOR COURT
CIVIL ACTION
DOCKET No.

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE
Plaintiff,
V.

COMPLAINT
BA YER CORPORATION
Defendant.

Plaintiff, State o f Maine, by and through Attorney General G. Steven Rowe, states as
follows:

STATEMENT OF THE CASE
1.

This is a civil action brought under the Maine Unfair Trade Practices Act, 5

M.R.S.A. § 205

et. seq.> alleging that Defendant, Bayer Corporation ("Bayer"), failed to

adequately warn prescribers and consumers and/or made false, misleading or deceptive
representations regarding the adverse side effects, safety, and efficacy o f Bayer's prescription
drug, Baycol. Bayer's conduct constitutes unfair and/or deceptive acts and practices in violation
o f the Maine Unfair Trade Practices Act.

JURISDICTION AND PARTIES
2.

The Attorney General is authorized to seek a judgment which enjoins fraudulent

or illegal business acts or practices, including any misrepresentation, concealment or suppression
o f a material fact, and which awards damages and restitution for such acts in an action in
Superior Court for Kennebec County. 5 M.R.S.A. § 209.

3.

Defendant Bayer Corporation (hereinafter "Bayer") is a corporation organized and

existing under the laws o f the State o f Indiana and is registered to conduct business in the State
o f Maine. Bayer is engaged in the trade or commerce o f researching, developing, manufacturing,
distributing, selling, and promoting drugs for use by Maine consumers in treating various
illnesses and diseases.

FACTUAL ALLEGATIONS
4.

Bayer is in the business of, among other things, researching, developing,

manufacturing, distributing, selling, and promoting drugs for use in treating various illnesses and
diseases.1
5.

Baycol, a “ statin” cholesterol-lowering prescription drug, was approved by the

FDA in 1997, and launched in the prescription market by Bayer in May o f 1998.
6.

While statin drugs carry a known risk o f myopathy and rhabdomyolysis, the risk

o f these adverse side effects with Baycol was significantly higher compared to other statins,
particularly at higher doses and when combined with genfibrozil, another cholesterol-lowering
drug.
7.

Bayer failed to adequately warn prescribes and consumers o f the greater risk o f

adverse side effects o f Baycol, including but not limited to myopathy and rhabdomyolysis,
8.

Bayer, has made or caused to be made, directly or indirectly, explicitly or by

implication, representations and omissions which are material, false and likely to mislead,
including, but not limited to the following:

Whenever reference is made in this complaint to any act or practice of the Defendant, such allegation shall be
deemed to mean that the principals, officers, directors, employees, agents, and representatives o f said Defendant did,
or authorized, such act or practice, on behalf of said Defendant while actively engaged in the scope of their duties.
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a.

That Baycol did not pose an increased risk o f myopathy and
rhabdomyolysis as compared to other statin drugs in mono-therapy.

b.
9.

That the use o f genfibrozil with Baycol was not contraindicated.

Contrary to Bayer's representations and omissions, Bayer:
a.

Knew or had reason to know that Baycol posed an increased risk o f
myopathy and rhabdomyolysis as compared to other statin drugs in mono
therapy.

b.

Knew or had reason to know that Baycol posed an increased risk o f
myopathy and rhabdomyolysis as compared to other statin drugs when
prescribed in combination with genfibrozil.

10.

A s a result o f Bayer's misrepresentations and omissions, consumers o f Baycol,

including state agencies that purchased or paid for Baycol pursuant to prescription drug
programs, were not aware o f the increased risk o f myopathy and rhabdomyolysis associated with
the use o f Baycol.

CAUSE OF ACTION
UNFAIR, UNCONSCIONABLE. OR DECEPTIVE ACTS OR PRACTICES
11.

5 M.R.S.A. § 209 authorizes the Attorney General to bring an action to enjoin a

defendant from engaging in a method, act, or practice that is unlawful under the Maine Unfair
Trade Practices Act.
12.

By engaging in the acts and practices described above, Bayer has engaged in

unfair, unconscionable, or deceptive acts and practices in violation o f 5 M.R.S.A. § 207.
13.

Bayer engaged in the acts and practices described above when it knew, or should

have known, that its conduct was unfair or deceptive in violation o f 5 M.R.S.A. § 207.
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PRAYER FOR RELIEF
WHEREFORE, the State o f Maine respectfully requests that a judgment and order be
entered that:
A.

Permanently enjoins Bayer from making any false, misleading or deceptive

representation regarding any o f its pharmaceutical or biological products in violation o f all
applicable laws and regulations.
B.

Directs Bayer to comply with all applicable laws and regulations relating to the

marketing, sale, and promotion o f its pharmaceutical and biological products.
C.

Directs Bayer to establish and maintain a clinical trial registry upon which Bayer

shall post summaries o f all clinical study reports for all studies conducted by Bayer on its
pharmaceutical or biological products.
D.

Directs Bayer to pay civil penalties for each willful violation o f 5. M.R.S.A. § 207

pursuant to 5 M.R.S.A. § 209.
E.

Awards Plaintiffs costs and attorneys fees, pursuant to 5 M.R.S.A. § 209.

F.

Grants all other relief as the Court deems appropriate.

Dated at Augusta, Maine this 23rd day o f January, 2007.

PLAINTIFF STATE OF MAINE
G. STEVEN ROWE
ATTORNEY GENERAL
BY:

'
Christina M. Moylan
Assistant Attorney General
Department o f Attorney General
6 State House Station
Augusta, Maine 04333-0006
Maine Bar No. 7095
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S tructure and Content

of

Clinical S tudy Reports

INTRODUCTION TO THE GUIDELINE

The objective of this guideline is to allow the compilation of a single core clinical study
report acceptable to all regulatory authorities of the ICH regions. The regulatory
authority specific additions will consist of modules to be considered as appendices,
available upon request according to regional regulatory requirements
The clinical study report described in this guideline is an "integrated" full report of an
individual study of any therapeutic, prophylactic or diagnostic agent (referred to
herein as drug or treatment) conducted in patients, in which the clinical and
statistical description, pr esentations, and analyses are integr ated into a single r epor t,
incorporating tables and figures into the main text of the report, or at the end of the
text, and with appendices containing the protocol, sample case report forms,
investigator related information, information related to the test dxugs/investigational
products including active control/comparators, technical statistical documentation,
related publications, patient data listings, and technical statistical details such as
derivations, computations, analyses, and computer* output etc. The integrated full
report of a study should not be derived by simply joining a separate clinical and
statistical report Although this guideline is mainly aimed at efficacy and safety
trials, the basic principles and structure described can be applied to other lands of
trials, such as clinical pharmacology studies.
Depending on the nature and
importance of such studies, a less detailed report might be appropriate.
The guideline is intended to assist sponsors in the development of a report that is
complete, free from ambiguity, well organised and easy to review. The report should
provide a clear' explanation of how the critical design features of the study were
chosen and enough information on the plan, methods and conduct of the study so that
there is no ambiguity in how the study was carried out.. The report with its
appendices should also provide enough individual patient data, including the
demographic and baseline data, and details of analytical methods, to allow replication
of the critical analyses when authorities wish to do so. It is also particularly
impor tant that all analyses, tables, and figur es carry, in text or as part of the table,
clear’identification of the set of patients from which they were generated.
Depending on the regulatory authority’s review policy, abbreviated reports using
summarised data or with some sections deleted, may be acceptable for uncontrolled
studies or other1studies not designed to establish efficacy (but a controlled safety
study should be reported in full), for seriously flawed or1 aborted studies, or for
contr olled studies that examine conditions clearly unr elated to those for which a claim
is made. However, a full description of safety aspects should be included in these
cases.. If an abbr eviated repor t is submitted, there should be enough detail of design
and results to allow the regulatory authority to determine whether a full report is
needed. If there is any question regarding whether' the reports are needed, it may be
useful to consult the regulatory authority.
In presenting the detailed description of how the study was carried out, it may be
possible simply to restate the description in the initial protocol. Often, however, it is
possible to present the methodology of the study more, concisely in a separate
document. In each section describing the design and conduct of the study, it is
particularly important to clarify features of the study that are not well-described in
1
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the protocol and identify ways in which the study as conducted differed from the
protocol, and to discuss the statistical methods and analyses used to account for these
deviations from the planned piotocol.
The lull integrated report of the individual study should include the most detailed
discussion of individual adverse events or laboratory abnormalities, hut these should
usually be reexamined as part of an overall safety analysis of all available data in any
application.
The report should describe demographic and other' potentially predictive
characteristics of the study population and, where the study is large enough to permit
this, present data for1demographic (e g., age, sex, race, weight) and other (e g., renal
or* hepatic function) subgroups so that possible differences in efficacy or' safety can be
identified. Usually, however, subgroup responses should he examined in the larger
database used in the overall analysis.
The data listings requested as part of' the report (usually in an appendix) are those
needed to support critical analyses. Data listings that are part of the report should be
readily usable by the reviewer'. Thus, although it may be desirable to include many
variables in a single listing to limit size, this should not be at the expense of clarity..
An excess of data should not be allowed to lead to over use of symbols instead of words
or easily understood abbreviations or to too small displays etc, In this case, it is
prefer able to produce several listings.
Data should be presented in the report at different levels of detail: overall summary
figures and tables for important demographic, efficacy and safety variables may be
placed in the text to illustrate important points; other summary figures, tables and
listings for' demographic, efficacy and safety variables should be pr ovided in section
14; individual patient data for specified groups of patients should be provided as
listings in Appendix 16.2; and all individual patient data (archival listings requested
only in the US) should be provided in Appendix 16 4
In any table, figure or data listing, estimated or derived values, if used, should he
identified in a conspicuous fashion Detailed explanations should be provided as to
how such values were estimated or derived and what underlying assumptions were
made.
The guidance provided below is detailed and is intended to notify the applicant of
virtually all of the information that should routinely be provided so that post
submission requests for further data clarification and analyses can be reduced as
much as possible Nonetheless, specific requirements for data presentation and/ or
analysis may depend on specific situations, may evolve over time, may vary from drug
class to drug class, may differ among regions and cannot be described in general
terms; it is therefore important to refer' to specific clinical guidelines and to discuss
data presentation and analyses with the reviewing authority, whenever possible.
Detailed written guidance on statistical approaches is available from some
authorities.
Each report should consider1all of the topics described (unless clearly not relevant)
although the specific sequence and gr ouping of topics may be changed if alternatives
are more logical for a particular study. Some data in the appendices are specific
requirements of individual regulatory authorities and should be submitted as
appropriate. The numbering should then be adapted accordingly.

2
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In the case of very large trials, some of the provisions of this guideline may be
impractical or inappropriate, When planning and when reporting such trials, contact
with regulatory authorities to discuss an appropriate report format is encouraged
The provisions of this guideline should be used in conjunction with other ICH
guidelines

STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS
X,

TITLE PAGE

The title page should contain the following information:
-

study title

- name of test drug/ investigational product
- indication studied
- if not apparent from the title, a brief (1 to 2 sentences) description giving design
(parallel, cross-over, blinding, randomised) comparison (placebo, active,
dose/response), duration, dose, and patient population
-

name of the sponsor

- protocol identification (code or number)
- development phase of'study
- study initiation date (first patient enrolled, or any other1verifiable definition)
-

date of early study termination, if any

- study completion date (last patient completed)
~ name and affiliation of principal or coordinating investigator^) or sponsor's
responsible medical officer
-

name of comp any/sponsor signatory (the person responsible for the study report
within the comp any/sponsor.. The name, telephone number and fax number of
the company/sponsor contact persons for1questions arising during review of the
study report should be indicated on this page or in the letter of application.)

- statement indicating whether the study was performed in compliance with Good
Clinical Practices (GCP), including the ar chiving of essential documents
- date of the report (identify any earlier reports from the same study by title and
date).
2.,
SYNOPSIS
A brief synopsis (usually limited to 3 pages) that summarises the study should be
provided (see Annex I of the guideline for an example of a synopsis format used in
Europe)., The synopsis should include numerical data to illustrate results, not just
text or p-values

3

StTuctuj e and Content o f Clinical Study Repoits

3,

TABLE OF CONTENTS FO R THE INDIVIDUAL CLINICAL STUDY
REPORT

The table of contents should include:
-

the page number or other locating information of each section, including
summary tables, figures and graphs;

- a list and the locations of appendices, tabulations and any case report forms
provided.
4,

LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

A list of the abbreviations, and lists and definitions o f specialised or unusual terms or
measurements units used in the report should be provided. Abbreviated terms should
be spelled out and the abbreviation indicated in parentheses at fust appear ance in the
text
5.,

ETHICS

0.1

INDEPENDENT ETHICS COMMITTEE (IEC) OR INSTITUTIONAL
REVIEW BOARD (IRB)
It should be confirmed that the study and any amendments were reviewed by an
Independent Ethics Committee or Institutional Review Board. A list of all IECs or
IRBs consulted should be given in appendix 16 1.3 and, if required by the regulatory
authority, the name of the committee Chair should be provided.
5.2

ETHICAL CONDUCT OF THE STUDY

It should be confirmed that the study was conducted in accordance with the ethical
principles that have their origins in the Declaration of Helsinki
5.3
PATIENT INFORMATION AND CONSENT
How and when informed consent was obtained in relation to patient enrolment, (e g,,
at allocation, pre-screening) should he described
Representative written information for the patient (if any) and a sample patient
consent form should be provided in appendix 16.1.3.
6,

INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

The administrative structure of the study (e g.., principal investigator, coordinating
investigator, steering committee, administration, monitoring and evaluation
committees, institutions, statistician, central laboratory facilities, contr act research
organisation (C..R.0 ), clinical trial supply management) should be described briefly in
the body of the repoi t .
There should be provided in appendix 16,1.4 a list of the investigators with their
affiliations, their' role in the study and their qualifications (curriculum vitae or’
equivalent). A similar list for' other' persons whose participation materially affected
the conduct of the study should also be provided in appendix 16,1,4. In the case of
large trials with many investigators the above requirements may be abbreviated to
consist of gener al statements of qualifications for persons carrying out particular roles
in the study with only the name, degree and institutional affiliation and roles of each
investigator or other participant.
The listing should include:
4
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a)
b)

Investigates
Any other person carrying out observations of primary or other' major
efficacy variables, such as a nurse, physician's assistant, clinical
psychologist, clinical pharmacist, or house staff physician
It is not
necessary to include in this list a person with only an occasional role, e g ,
an on-call physician who dealt with a possible adverse effect or a temporary
substitute for any of the above

c)

The author(s) o f the report, including the responsible biostatistician(s)

Where signatures of the principal or coordinating investigators axe required by
regulatory authorities, these should be included in appendix 16.1.6 (see Annex II for a
sample form). Where these are not required, the signature of the sponsor's
responsible medical officer should be provided in appendix 16.1 5.
7.
INTRODUCTION
The introduction should contain a brief statement (maximum: 1 page) placing the
study in the context of the development of the test drug/investigational product,
relating the critical features of the study (e..g., rationale and aims, target population,
treatment, duration, primary endpoints) to that development.. Any guidelines that
were followed in the development of the pr otocol or any other agreements/meetings
between the sponsor/eompany and regulatory authorities that are relevant to the
particular' study, should be identified or described
8„
STUDY OBJECTIVES
A statement describing the overall purpose(s) of the study should be provided,
ft.

INVESTIGATIONAL PLAN

9,1

OVERALL STUDY DESIGN AND PLAN - DESCRIPTION

The overall study plan and design (configuration) of the study (e g,, parallel, cross
over) should be described briefly but clearly, using charts and diagrams as needed If
other studies used a very similar' protocol, it may be useful to note this and describe
any important differences. The actual protocol and any changes should be included as
appendix 16.1.1 and a sample case report form (unique pages only; i.e, it is not
necessary to include identical pages from forms for different evaluations or visits) as
appendix 16.1.2. If any of the information in this section comes from sources other
than the protocol, these should be identified.
The information provided should include:
~ treatments studied (specific drugs, doses and procedures);
~ patient population studied and the number of patients to be included;
-

level and method ofbhnding/m asking (e.g., open, double-blind, single-blind,
blinded evaluator s and unblinded patients and/or investigators);

~ land of controls) (e.g., placebo, no treatment, active drug, dose-response,
historical) and study configuration (par allel, cross-over );
- method of assignment to treatment (randomisation, stratification);
~ sequence and dur ation of all study periods, including pre-randomisation and
post-tr eatment periods, therapy withdrawal periods and single- and double
blind treatment periods. When patients are randomised should be specified.

5
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It is usually helpful to display the design graphically with a flow chart which
includes timing of assessments (see Annexes Ilia and Illb'for an example);
-

any safety, data monitoring or special steeling oi evaluation committees;

-

any interim analyses.

92

DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF
CONTROL GROUPS
The specific control chosen and the study design used should be discussed, as
necessary.. Examples of design issues meriting discussion follow.
Generally, the control (comparison) groups that are recognised are placebo concurrent
control, no treatment concurrent control, active treatment concurrent control, dose
comparison concurrent control, and historical control. In addition to the type of
control, other critical design features that may need discussion are use of a cross-over
design and selection of patients with particular prior history, such as response or non
response to a specific drug or member of a drug class. If randomisation was not used,
it is important to explain how other1techniques, if any, guarded against systematic
selection bias,
Known or potential problems associated with the study design or control group
chosen, should be discussed in light of the specific disease’ and therapies being
studied. For1a crossover1design, for1example, there should be consideration, among
other things, of the likelihood of spontaneous change in the disease and of carry-over
effects of treatment during the study .
If efficacy was to be demonstrated by showing equivalence, i.e.., the absence o f a
specified degree of inferiority of the new treatment compared to an established
treatment, problems associated with such study designs should he addressed.
Specifically there should be provided a basis for considering the study capable of
distinguishing active from inactive therapy.. Support may be provided by an analysis
of previous studies similar to the present study with respect to important design
characteristics (patient selection, study endpoints, duration, dose of active control,
concomitant ther apy etc ) showing a consistent ability to demonstrate superiority of
the active control to placebo,. How to assess the ability of the present study to
distinguish effective from ineffective therapy should also be discussed, For1example,
it may be possible to identify a treatment response (based on past studies) that would
clearly distinguish between the treated population and an untreated group Such a
response could be the change of a measure from baseline or some other specified
outcome like healing rate or1 survival rate. Attainment of such a response worrld
support the expectation that the study could have distinguished the active drug from
an inactive drug. There should also be a discussion of the degree of inferiority of the
therapy (often referred to as the delta value) the study was intended to show was not
exceeded.
The limitations of historical controls are well known (difficulty of assuring
comparability of treated groups, inability to blind investigators to treatment, change
in fcherapy/disease, difference due to placebo effect etc.) and deserve particular1
attention,
Other specific featur es of the design may also deserve discussion, including presence
or1absence of washout periods and the dur ation of the treatment period, especially for
a chronic illness. The rationale for dose and dose-interval selection should be
explained, if it is not obvious For example, once daily dosing with a short half-life
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drug whose effect is closely r elated in time to blood level is not usually effective; if the
study design uses such dosing, this should be explained, e..g., by pointing to
pharmacodynamic evidence that effect is prolonged compared to blood levels. The
procedures used to seek evidence of "escape" from drug effect at the end of the doseinterval, such as measurements of effect just prior to dosing, should he described.
Similarly, in a parallel design dose-response study, the choice of doses should be
explained
9.3

SELECTION OF STUDY POPULATION

9.3.1 Inclusion Criteria
The patient population and the selection criteria used to enter' the patients into the
study should be described, and the suitability of the population for the purposes of the
study discussed,
Specific diagnostic criteria used, as well as specific disease
requirements (e g., disease of a particular severity or' duration, results of a particular
test or rating scale(s) or physical examination, particular features of clinical history,
such as failure or success on prior therapy, or other potential prognostic factors and
any age, sex or ethnic factors) should be presented.
Screening criteria and any additional criteria for randomisation or entry into the test
drug/investigational product treatment part of the trial should be described If there
is reason to believe that there were additional entry criteria, not defined in the
protocol, the implications of these should be discussed.
For example, some
investigators may have excluded, or entered into other studies, patients who were
particularly ill or who had particular baseline char acteristics,
9. 3,2 Exclusion Cr iteria
The criteria for exclusion at entry into the study should be specified and the rationale
(e g , safety concer ns, administrative reasons or lack of suitability for the trial)
provided. The impact of exclusions on the gener alls ability of the study should be
discussed in section 13 of the study report, or in an overview of safety and efficacy.
9.3.3

Removal of Patients from Therapy or Assessment
The predetermined reasons for removing patients hom therapy or assessment
observation, if any, should be described, as should the nature and duration of
any planned follow-up observations in those patients.

9.4

TREATMENTS

9.4.1 Treatments Administer ed
The pr ecise treatments or diagnostic agents to be administered in each arm of the
study, and for each period of the study, should be described including route and mode
of administration, dose and dosage schedule,
9 .4.,2 Identity of Investigational Prodxtet(s)
In the text of the report, a brief description of the test dr ug(s)/investigational
product(s) (formulation, strength, batch number(s)) should be given, If more than one
batch of test drug/investigational product was used, patients receiving each batch
should be identified in appendix 16,1.6,
The source of placebos and active control/comparator product(s) should be provided.
Any modification of comparator product(s) fr om their' usual commer cial state should
7
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be noted, and the steps taken to assure that their bioavailability was unaltered should
be described.
For' long-duration trials o f investigational products with limited shelf-lives or
incomplete stability data, the logistics of resupply of the materials should be
described Any use of test materials past their expiry date should be noted, and
patients receiving them identified, If there were specific storage requirements, these
should also be described,
9.4.3

Method of Assigning Patients to Treatment Groups

The specific methods used to assign patients to treatment groups, e g,( centralised
allocation, allocation within sites, adaptive allocation (that is, assignment on the basis
of earlier assignment or outcome) should be described in the text of the report,
including any stratification or blocking procedures. Any unusual features should he
explained.
A detailed description of the randomisation method, including how it was executed,
should be given in appendix 16,1,7 with references cited if' necessary A table
exhibiting the randomisation codes, patient identifier, and treatment assigned should
also be presented in the appendix. For a multicentre study, the information should be
given by centre. The method of generating random numbers should be explained.
For* a historically controlled trial, it is important to explain how the particular' control
was selected and what other historical experiences were examined, if any, and how
their results compar ed to the control used
9.4.4 Selection of Doses in the Study
The doses or dose ranges used in the study should he given for all treatments and the
basis for choosing them described (e.g , prior experience in humans, animal data).
9.4.5

Selection and Timing of Dose for each Patient

Procedures for selecting each patient’s dose of test drug/investigational product and
active control/compar ator should be described. These procedures can vary from
simple random assignment to a selected fixed drug/dose regimen, to some specified
titration procedure, to more elaborate response-determined selection procedures, eg.,
where dose is titrated upward at intervals until intolerance or some specified
endpoint is achieved. Procedures for back-titration, if any, should also be described
The timing (time o f day, interval) of dosing and the relation o f dosing to meals should
be described, and if it was not specified, this should be noted
Any specific instr uctions to patients about when or how to take the dose(s) should he
described.
9.4.6 B linding
A description of the specific procedur es used to carry out blinding should be pr ovided
(e g,, how bottles were labelled, labels that reveal blind-breakage, sealed code
list/envelopes, double dummy techniques), including the circumstances in which the
blind would be broken for an individual or for all patients, eg., for- serious adverse
events, the procedures used and who had access to patient codes. If the study allowed
for' some investigators to remain unblinded (e,g., to allow them to adjust medication),
the means of shielding other investigators should be explained. Measures taken to
ensure that test drug/investigational product and placebo were indistinguishable and
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evidence that they weie indistinguishable, should be described, as should the
appearance, shape, smell, and taste of the test material. Measures to prevent
unblinding by laboratory measurements, if used, should be described. If there was a
data monitoring committee with access to unblinded data, procedures to ensure
maintenance of overall study blinding should be described. The procedure to
maintain the blinding when interim analyses are performed should also be explained.
If blinding was considered unnecessary to reduce bias for some or all o f the
observations, this should be explained; eg., use of a random-zero sphygmomanometer
eliminates possible observer bias in reading blood pressure and Holter tapes are often
read by automated systems that are presumably immune to observer bias. If blinding
was considered desirable but not feasible, the reasons and implications should be
discussed Sometimes blinding is attempted but is known to be imperfect because of
obvious drug effects in at least some patients (dry mouth, bradycardia, fever, injection
site reactions, changes in laboratory data).. Such problems or potential problems
should be identified and if there wer e any attempts to assess the magnitude of the
problem or manage it (e g., by having some endpoint measurements carried out by
people shielded from information that might reveal treatment assignment), they
should be described.
9,4.7 Prior and Concomitant Therapy
Which drugs or procedures were allowed before and during the study, whether and
how their use was recorded, and any other specific rules and procedures related to
permitted or forbidden concomitant therapy should be described. How allowed
concomitant therapy might affect the outcome due either' to drug-drug interaction or
to direct effects on the study endpoints should be discussed, and how the independent
effects of concomitant and study therapies could be ascertained should be explained
9.4.. 8

Tr eatment Compliance

The measures taken to ensure and document treatment compliance should be
described, e g., drug accountability, diary cards, blood, mine or other body fluid drug
level measurements, or medication event monitoring.
9..B

EFFICACY AND SAFETY VARIABLES

9,5 ,1 Efficacy and Safety Measurements Assessed and Flow Chart
The specific efficacy and safety variables to be assessed and laboratory tests to be
conducted, their schedule (days of study, time of day, r elation to meals, and the timing
of critical measures in relation to test drug administration, eg., just prior to next
dose, two horns after dose), the methods for measuring them, and the persons
responsible for the measurements should be described. If there were changes in
personnel carrying out critical measurements, these should he reported,
It is usually helpful to display graphically in a flow chart (see Annex III of' the
guideline) the frequency and timing of efficacy and safety measurements; visit
numbers and times should be shown, or, alternatively, times alone can be used (visit
numbers alone are more difficult to interpret). Any specific instructions (e,g.,
guidance or use of a diary) to the patients should also be noted.
Any definitions used to characterise outcome (e..g.., criteria for determining occurrence
of acute myocardial infarction, designation of the location of the infarction,
characterisation of a stroke as thrombotic or haemorrhagic, distinction between TIA
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and stroke, assignment of cause of death) should be explained in full. Any techniques
used to standardise or compare results of laboratory tests or other clinical
measurements (e g., ECG, chest X-ray) should also be described,. This is particularly
impor tant in multicentre studies.
If anyone other' than the investigator was responsible for evaluation of clinical
outcomes (e g., the sponsor or an external committee to review X-rays or ECG’s or to
determine whether1the patient had a stroke, acute infarction, or1sudden death) the
per son or gr oup should be identified. The pr ocedur es, including means of maintaining
blindness, and centralising readings and measur ements, should be described fully..
The means of obtaining adverse event data should be described (volunteered,
checklist, or, questioning), as should any specific rating scalefs) used and any
specifically planned follow-up procedures for adverse events or any planned
reehallenge procedrue.
Any rating of adverse events by the investigator, sponsor- or- external group, (e g ,
rating by severity or, likelihood of drug causation) should be described The criteria
for such ratings, if any, should be given and the parties responsible for1the ratings
should be clearly identified,
If efficacy or safety was to be assessed in terms of
categorical r atings, numerical scores etc., the criteria used for point assignment (e.g..,
definitions of point scores) should be provided For1multicentre studies, indicate how
methods were standardised
9..S.2 Appropriateness of Measurements
If any of the efficacy or safety assessments was not standard, ie., widely used and
generally recognised as reliable, accurate, and relevant (able to discriminate between
effective and ineffective agents), its reliability, accuracy and relevance should be
documented. It may he helpful to describe alternatives considered but rejected.
If a surrogate end point (a laboratory measurement or physical measurement or sign
that is not a direct measure of clinical benefit) was used as a study end point, this
should be justified eg., by reference to clinical data, publications, guidelines or
previous actions by regulatory authorities.
9.5.3

Primary Efficacy Var iable(s)

The primary measurements and endpoints used to determine efficacy should be
clearly specified Although the critical efficacy measurements may seem obvious,
when there are multiple variables, or1when variables are measured repeatedly, the
protocol should identify the primary ones, with an explanation of why they were
chosen, or1designate the pattern of significant findings or other method of combining
information that would be interpreted as supporting efficacy. If the protocol did not
identify the primary variables, the study report should explain how these critical
variables were selected (e ,g.., by reference to publications, guidelines or previous
actions by regulatory authorities) and when they were identified (ie., before or after
the study was completed and unblinded). If an efficacy threshold was defined in the
protocol, this should be described.
9.5.4 Drug Concentration Measurements
Any drug concentrations to be measured, and the sample collection times and periods
in relation to the timing of drug administration, should be described. Any relation of
drug administr ation and sampling to ingestion of food, posture and the possible
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effects of concomitant medicafcion/alcohol/caffeine/nicotine should also be addressed.
The biological sample measured the handling of samples and the method of
measurement used should be described, referring to published and/or internal assay
validation documentation for methodological details. Where other1factors are believed
important in assessing pharmacokinetics (e g., soluble circulating receptors, renal or
hepatic function), the timing and plans to measure these factors should also be
specified.
9.6
DATA QUALITY ASSURANCE
The quality assur ance and quality contr ol systems implemented to assur e the quality
of the data should be described in brief. If' none were used, this should be stated..
Documentation of inter-labor ator y standar disation methods and quality assur ance
procedures, if used, should be provided under appendix 16.110.
Any steps taken at the investigation site or centrally to ensure the use of standard
terminology and the collection of accurate, consistent, complete, and reliable data,
such as training sessions, monitoring of investigators by sponsor personnel,
instruction manuals, data verification,, cross-checking, use of a central laboratory for
certain tests, centralised ECG reading, or data audits, should be described. It should
be noted whether investigator meetings or other steps were taken to prepare
investigators and standardise performance.
If the sponsor1used an independent internal or1external auditing procedure, it should
he mentioned here and described in appendix 16.1.8; and audit certificates, if
available, should be provided in the same appendix.
9.7

STATISTICAL METHODS PLANNED IN THE PROTOCOL AND
DETERMINATION OF SAMPLE SIZE

9.7.1 Statistical and Analytical Plans
The statistical analyses planned in the protocol and any changes made before outcome
results were available should be described. In this section emphasis should be on
which analyses, comparisons and statistical tests were planned, not on which ones
were actually used
I f critical measurements were made more than once, the
particular1 measurements (e.g., average of several measurements over the entire
study, values at particular1 times, values only from study completers, or last ontherapy value) planned as the basis for comparison of test drug/investigational
product and control should be specified.. Similarly, if more than one analytical
approach is plausible, e.g, changes from baseline response, slope analysis, life table
analysis, the planned approach should be identified Also, whether the primary
analysis is to include adjustment for covariates should be specified.
If there wer e any planned reasons for1excluding fr om analysis patients for whom data
are available, these should be described, If there were any subgroups whose results
were to be examined separately, these should be identified, If categorical responses
(global scales, severity scores, responses of a certain size) were to be used in analysing
responses, they should be clearly defined
Planned monitoring of the results of the study should be described, If there was a
data monitoring committee, either within or outside the sponsor's control, its
composition and operating procedures should be described and procedures to maintain
study blinding should be given. The frequency and nature of any planned interim
analysis, any specified circumstances in which the study would be terminated and any
11
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statistical adjustments to be employed because of interim analyses should be
described.
9.7 ,2 Determination of Sample Size
The planned sample size and the basis for it, such as statistical considerations or
practical limitations, should be provided. Methods for' sample size calculation should
be given together with their derivations or1sour ce of r efer ence. Estimates used in the
calculations should be given and explanations provided as to how they were obtained.
For* a study intended to show a difference between treatments, the difference the
study is designed to detect should be specified. For a positive control study intended
to show that a new therapy is at least as effective as the standard therapy, the sample
size determination should specify the difference between treatments that would be
considered unacceptably large and therefore the difference the study is designed to be
able to exclude.
9.8

CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED
ANALYSES
Any change in the conduct of the study or planned analyses (e.g., dropping a
treatment group, changing the entry criteria or drug dosages, adjusting the sample
size etc.) instituted after the start of the study should be described. The time(s) and
reason(s) for the change(s), the procedure used to decide on the change(s), the
person(s) or group(s) responsible for the change(s) and the nature and content of the
data available (and to whom they wer e available) when the change was made should
also he described, whether1 the change was documented as a formal protocol
amendment or not (Personnel changes need not be included).
Any possible
implications of the change(s) for1the interpretation of the study should be discussed
briefly in this section and more fully in other appropriate sections of the report. In
every section of the report, a clear distinction between conditions (procedures)
planned in the protocol and amendments or additions should he made. In general,
changes in planned analyses made prior to breaking the blind have limited
implications for study interpretation. It is therefore particularly critical that the
timing of changes relative to blind breaking and availability of outcome results be
well characterised,
10.

STUDY PATIENTS

10,1

DISPOSITION OF PATIENTS

There should he a clear accounting of all patients who enter ed the study, using figures
or tables in the text of the report. The numbers of patients who were randomised, and
who entered and completed each phase of the study, (or each week/month of the
study) should be provided, as well as the reasons for1 all post-randomisation
discontinuations, grouped by treatment and by major reason (lost to foliow-up,
adver se event, poor compliance etc.) It may also be r elevant to provide the number of
patients screened for inclusion and a breakdown of the reasons for1excluding patients
during screening, if this could help clarify the appropriate patient population for
eventual drug use A flow chart is often helpful (see Annexes IVa and IVb of the
guideline for example). Whether patients are followed for the duration o f the study,
even if drug is discontinued, should be made dear
In appendix .16.2.1, there should also be a listing of all patients discontinued from the
study after enrolment, broken down by centre and treatment gr oup, giving a patient
identifier, the specific reason for discontinuation, the treatment (drug and dose),
12
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cumulative dose, (where appropriate), and the duration of' treatment before
discontinuation. Whether' or not the blind for the patient was broken at the time of
discontinuation should be noted. It may also be useful to include other' information,
such as critical demographic data ( e g , age, sex, race), concomitant medication, and
the major response vaiiable(s) at termination. See Annex V for an example of such a
listing.
10.2 PROTOCOL DEVIATIONS ’
All important deviations related to study inclusion or1exclusion criteria, conduct of the
trial, patient management or patient assessment should be described..
In the body of the text, protocol deviations should be appropriately summarised by
centre and grouped into different categories, such as:
-

those who entered the study even though they did not satisfy the entry
criteria;

-

those who developed withdrawal criteria during the study but were not
withdrawn;

-

those who received the wrong treatment or incorrect dose;

-

those who received an excluded concomitant tr eatment

In appendix 16.2.2, individual patients with these protocol deviations should be listed,
broken down by centre for multicentre studies
11,

EFFICACY EVALUATION

11.1 DATA SETS ANALYSED
Exactly which patients were included in each efficacy analysis should be precisely
defined, e g., all patients receiving any test drugs/investigational products, all
patients with any efficacy observation or with a certain minimum number of
observations, only patient« completing the trial, all patients with an observation
during a particular time window, only patients with a specified degree of compliance
etc. It should be clear', if not defined in the study protocol, when, (relative to study
unblinding), and how inclusion/exclusion criteria for' the data sets analysed were
developed. Generally, even if the applicant’s proposed primary analysis is based on a
reduced subset of the patients with data, there should also be for' any trial intended to
establish efficacy an additional analysis using all randomised (or otherwise enter ed)
patients with any on-treatment data.
There should be a tabular listing of all patients, visits and observations excluded from
the efficacy analysis provided in appendix 16,2.3 (see Annex VI of the guideline for1an
example) The r easons for exclusions should also be analysed for the whole tr eatment
group over1time (see Annex VII of the guideline for1an example).
11.2 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Group data for the critical demographic and baseline characteristics of the patients,
as well as other1factors arising dining the study that- could affect response, should be
presented in this section and comparability of the treatment groups for all relevant
characteristics should be displayed by use of tables or graphs in section 14,1, The
data for the patient sample included in the "all patients with data" analysis should be
given first This can then be followed by data on other groups used in principal
analyses, such as the "per-protocol" analysis or other' analyses, e.g., groups defined by
compliance, concomitant disease/therapy, or demographic/baseline characteristics
13
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When such groups are used, data for the complementary excluded group should also
be shown. In a multicentre study where appropriate, comparability should be
assessed by centre, and centres should be compared.
A diagr am showing the r elationship between the entire sample and any other1analysis
groups should be provided.
The critical variables will depend on the speciiic nature of the disease and on the
protocol but will usually include:
> demographic variables
-

age

- sex
-

race

> disease factors
-

specific entry criteria (if not uniform), duration, stage and severity of
disease and other clinical classifications and sub-groupings in common
usage or of known prognostic significance

- baseline values for critical clinical measurements carried out during the
study or identified as important indicators of prognosis or response to
ther apy
-

concomitant illness at trial initiation, such as renal disease, diabetes,
heart failure

- r elevant previous illness
- relevant previous treatment for illness treated in the study
-

concomitant treatment maintained, even if the dose was changed during
the study, including oral contraceptive and hormone replacement
ther apy; treatments stopped at entry into the study period (or1changed at
study initiation)

> other factors that might affect response to therapy (e..g, weight, renin status,
antibody levels, metabolic status)
> other possibly relevant variables (e g., smoking, alcohol intake, special diets)
and, for women, menstrual status and date of' last menstrual period, if
pertinent for the study.
In addition to tables and graphs giving group data for these baseline variables,
relevant individual patient demographic and baseline data, including laboratory
values, and all concomitant medication for all individual patients r andomised (br oken
down by treatment and by centre for multicentre studies) should be presented in bypatient tabular listings in appendix 16 2,4, Although some regulatory authorities will
requir e all baseline data to be presented elsewhere in tabular listings, the appendix to
the study report should be limited to only the most relevant data, generally the
variables listed above.
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11.8

MEASUREMENTS OF TREATMENT COMPLIANCE

Any measuiements of compliance of individual patients with the treatment regimen
under1study and drug concentrations in body fluids should be summarised, analysed
by treatment group and time interval, and tabulated in Appendix 16.2.5,.
11.4

EFFICACY RESULTS AND TABULATIONS OF INDIVIDUAL PATIENT
DATA

11.,4,1 Analysis o f E fficacy'
Treatment groups should be compared for all critical measures of efficacy (primary
and secondary end-points; any pharmacodynamic end points studied), as well as
benefit/risk assessment^) in each patient where these are utilised. In general, the
results of all analyses contemplated in the protocol and an analysis including all
patients with on-study data should be performed in studies intended to establish
efficacy. The analysis should show the size (point estimate) of the difference between
the treatments, the associated confidence interval, and where utilised, the results of
hypothesis testing.
Analyses based on continuous variables (e g., mean blood pressure or depression scale
score) and categorical responses (e g., cure of an infection) can be equally valid;
ordinarily both should he presented if both were planned and are available. If
categories are newly created, (i.e., not in the statistical plan) the basis for them
should be explained. Even if one variable receives primary attention (e g,, in a blood
pressure study, supine blood pressure at week x), other reasonable measures (e„g ,
standing blood pressure and blood pressures at other particular times) should be
assessed, at least briefly. In addition, the time course of response should be
described, if possible. For1a multicentre study, where appropriate, data display and
analysis of individual centr es should be included for critical variables to give a clear
picture of the results at each site, especially the larger sites.
If any critical measurements or assessments of efficacy or* safety outcomes wer e made
by more than one party (e..g , both the investigator and an expert committee may offer
an opinion on whether a patient had an acute infarction), overall differences between
the ratings should be shown, and each patient having disparate assessments should
be identified, The assessments used should be clear in all analyses.
In many cases, efficacy and safety endpoints are difficult to distinguish, (e g,., deaths
in a fatal disease study), Many of the principles addressed below should be adopted
for critical safety measures as well.
11,4,2 Statist!cal/Analytieal Issues
The statistical analysis used should he described for1clinical and statistical reviewer s
in the text of the report, with detailed documentation of statistical methods (see
section Annex IX) presented in appendix 16.1.9, Important features of the analysis
including the particular methods used, adjustments made for demographic or baseline
measuiements or concomitant therapy, handling of drop-outs and missing data,
adjustments for multiple comparisons, special analyses o f multicentre studies, and
adjustments for interim analyses, should be discussed. Any changes in the analysis
made after blind-breaking should he identified.
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In addition to the general discussion the following specific issues should be addressed
(unless not applicable):
n.4.2.1
Adjustments for Covariates
Selection of, and adjustments for, demographic or baseline measurements,
concomitant therapy, or any other covariate or prognostic factor' should be explained
in the report, and methods of adjustment, results of analyses, and supportive
information (e g., ANCOVA or Cox regression output) should be included in the
detailed documentation of statistical methods, If the covariates or methods used in
these analyses differed from those planned in the protocol, the differences should be
explained and where possible and relevant, the results of planned analyses should
also be presented. Although not part of the individual study r eport, comparisons of
covariate adjustments and prognostic factors across individual studies may be an
infor mative analysis in a summary of clinical efficacy data..
11,4,2,2 Handling of Dropouts or Missing Data
There are several factors that may affect dropout rates. These include the duration of
the study, the nature of the disease, the efficacy and toxicity of the drug under' study,
and other factors that are not therapy related. Ignoring the patients who dropped out
of the study and dr awing conclusions based only on patients who completed the study
can be misleading.. A large number of dropouts, however1, even if included in an
analysis, may introduce bias, particularly if there are more early dropouts in one
treatment group or the reasons for dropping out are treatment or' outcome related
Although the effects o f early dropouts, and sometimes even the dir ection of bias, can
be difficult to determine, possible effects should be explored as fully as possible. It
may be helpful to examine the observed cases at various time points or, if dropouts
were very frequent, to concentrate on analyses at time points when moat of the
patients were still under observation and when the full effect of the dr ug was realised
It may also be helpful to examine modelling approaches to the evaluation of such
incomplete data sets.
The results of a clinical trial should be assessed not only for the subset of patients
who completed the study, but also for the entire patient population as randomised or1
at least for all those with any on-study measurements. Several factors need to be
considered and compared for the treatment groups in analysing the effects of
dropouts: the reasons for the dropouts, the time to dropout, and the proportion of
dr opouts among treatment gr oups at various time points
Procedures for dealing with missing data, e g,, use of estimated or derived data,
should be described. Detailed explanation should be provided as to how such
estimations or derivations were done and what underlying assumptions were made
11,4.,2.,3

Interim Analyses and Data Monitor ing

The process of examining and analysing data accumulating in a clinical trial, either
formally or' informally, can introduce bias and/or increase type I error1. Therefore, all
interim analyses, formal or informal, pre-planned or ad hoc, by any study participant,
sponsor staff member , or data monitoring group should be described in full, even if
the treatment groups were not identified The need for statistical adjustment because
of such analyses should be addr essed . Any operating instr uctions or procedur es used
for such analyses should be described. The minutes of meetings of any data
monitoring group and any data reports reviewed at those meetings, particularly a
meeting that led to a change in the protocol or early termination of the study, may be
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helpful and should be piovided in appendix 16,1.9. Data monitoring without codebreaking should also be described, even if this kind of monitoring is considered to
cause no increase in type I error..
11..4.2.4

Multicentre Studies

A multicentre study is a single study under1 a common protocol, involving several
centres (e g., clinics, practices, hospitals) where the data collected are intended to be
analysed as a whole (as opposed to a post-hoc decision to combine data or results from
separate studies). Individual centre results should be presented, however, where
appropriate, e.g., when the centres have sufficient numbers of patients to make such
analysis potentially valuable, the possibility of qualitative or quantitative treatmentby-centre interaction should be explored, Any extreme or opposite results among
centres should be noted and discussed, considering such possibilities as differences in
study conduct, patient characteristics, or clinical settings Treatment comparison
should include analyses that allow for1centre differences with respect to response.. If
appropriate, demographic, baseline, and post-baseline data, as well as efficacy data,
should be presented by centre, even though the combined analysis is the primary one.
11„4„2.5 Multiple Comparison/Multiplicity
False positive findings increase in number- as the number- of significance tests
(number of comparisons) performed increases. If there was more than one primary
endpoint (outcome variable), mor e than one analysis of particular endpoint, or if ther e
were multiple treatment groups, or subsets of the patient population being examined,
the statistical analysis should reflect awareness of this and either1 explain the
statistical adjustment used for type I error criteria or give reasons why it was
considered unnecessary.,
11..4..2..6

Use of an "Efficacy Subset" of Patients

Particular1 attention should be devoted to the effects of dropping patients with
available data from analyses because of poor compliance, missed visits, ineligibility,
or any other reason As noted above, an analysis using all available data should be
carried out for all studies intended to establish efficacy, even if it is not the analysis
pr oposed as the primary analysis by the applicant. In general, it is advantageous to
demonstrate robustness o f the principal trial conclusions with respect to alternative
choices of patient populations for analysis Any substantial differences resulting from
the choice of patient population for analysis should be the subject of explicit
discussion.
11.4.2,7

Active-Control Studies Intended to Show Equivalence

If an active control study is intended to show equivalence (i e , lack of a difference
greater1than a specified size) between the test diug/investigational product and the
active contiol/comparator, the analysis should show the confidence interval for the
comparison between the two agents for critical end points and the relation of that
interval to the prespecified degree of inferiority that would be considered
unacceptable.. (See 9 2, for important considerations when using the active control
equivalence design.)
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11..4.2..8

Examination of Subgroups

If the size of the study permits, important demogiaphic or baseline value-defined
subgroups should be examined for unusually lar ge oi small responses and the results
presented, e,.g, comparison of effects by age, sex, or race, by severity or prognostic
groups, by history of prior treatment with a ding of the same class etc. If these
analyses were not carried out because the study was too small it should be noted,
These analyses are not intended to "salvage” an otherwise non-supportive study but
may suggest hypotheses worth examining in other studies 02 be helpful in refining
labelling infoimation, patient selection, dose selection etc. Where there is a prior
hypothesis of a differential effect in a particular subgroup, this hypothesis and its
assessment should be part o f the planned statistical analysis
11.4.3 Tabulation of Individual Response Data
In addition to tables and gr aphs representing group data, individual response data
and other relevant study information should be presented in tables. Some regulatory
authorities may require all individual data in archival case report tabulations. What
needs to be included in the report will vary from study to study and from one drug
class to another and the applicant must decide, if possible after consultation with the
regulatory authority, what to include in appendix to the study report. The study
report should indicate what material is included as an appendix, what is in the more
extensive ar chival case repor t tabulations, if required by the regulator y authority, and
what is available on request.
For a controlled study in which critical efficacy measurements or assessments (e..g.,
blood or urine cultures, pulmonary function tests, angina frequency, or global
evaluations) are repeated at intervals, the data listings accompanying the report
should include, for' each patient, a patient identifier, all measured or observed values
of critical measur ements, including baseline measurements, with notation of the time
during the study (e..g„, days on therapy and time of day, if relevant) when the
measurements were made, the drug/dose at the time (if useful, given as mg/kg), any
measurements of compliance, and any concomitant medications at the time of, or close
to the time of, measurement or assessment. If, aside from repeated assessments, the
study included some overall responder vs non-responder evaluation^), (bacteriologic
cine or failure), it should also be included In addition to critical measurements, the
tabulation should note whether1the patient was included in the efficacy evaluation
(and which evaluation, if more than one), provide patient compliance infoimation, if
collected, and a reference to the location of the case report form, if included,. Critical
baseline information such as age, sex, weight, disease being treated (if more than one
in study), and disease stage or severity, is also helpful The baseline values for
critical measurements would ordinarily be included as zero time values for each
efficacy measurement.
The tabulation described should usually be included in appendix 16 .2.6 of the study
report, rather than in the more extensive case report tabulations required by some
regulatory authorities, because it represents the basic efficacy data supporting
summary tables. Such a thorough tabulation can be unwieldy for- review purposes,
however, and it is expected that more targeted displays will be developed as well. For
example, if ther e are many measur ements r eported, tabulations of the most critical
measurements for each patient (e g,, the blood pressure value at certain visits might
be more important than others) will be useful in providing an overview of each
individual's results in a study, with each patient's response summarised on a single
line or small number1of lines.
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11.4.. 4 Drug Dose, Drug Concentration, and Relationships to Response
When the dose in each patient can vary, the actual doses received by patients should
be shown and individual patient's doses should be tabulated. Although studies not
designed as dose-response studies may have limited ability to contribute doseresponse information, the available data should be examined for whatever
information they can yield.. In examining the dose response, it may be helpful to
calculate dose as mg/kg body weight or ing/m2 body surface.
Drug concentration information, if available, should also be tabulated (Appendix
16 2 5), analysed in phar macokinetic terms and, if possible, related to response.
Further guidance on the design and analysis of studies exploring dose-response or
concentration response can be found in the ICH Guideline "Dose-Response
Information to Support Drug Registration".
11,4.5 Drug-Drug and Drug-Disease Inter actions
Any apparent relationship between response and concomitant therapy and between
response and past and/or concurrent illness should be described.
11.4.. 6 By-Patient D isplays
While individual patient data ordinarily can be displayed in tabular listings, it has on
occasion been helpful to construct individual patient profiles in other formats, such as
graphic displays.. These might, for example, show the value of (a) particular
parameter^) over time, the drug dose over the same period, and the times of
particular events (e..g., an adverse event or change in concomitant therapy) Where
group mean data repr esent the principal analyses, this kind of "case report extract”
may offer' little advantage; it may be helpful, however, if overall evaluation of
individual responses is a critical part of the analysis.
11,4,7 E fficacy C onclusions
The important conclusions concerning efficacy should be concisely described,
considering primary and secondary end points, pre-specified and alternative
statistical approaches and results of exploratory analyses.
12.
SAFETY EVALUATION
Analysis of safety-related data can be considered at three levels. First, the extent of
exposure (dose, duration, number of patients) should be examined to determine the
degree to which safety can be assessed from the study. Second, the more common
adverse events, laboratory test changes etc., should be identified, classified in some
reasonable way, compared for treatment groups, and analysed, as appropriate, for'
factors that may affect the frequency of adverse reactions/events, such as time
dependence, relation to demographic characteristics, relation, to dose or drug
concentration etc, Finally, serious adverse events and other1 significant adverse
events should be identified, usually by close examination of patients who left the
study prematurely because of an adverse event, whether or not identified as drug
related, or who died.
The ICH Guideline on Clinical Safety Data Management, Definitions and Standards
for Expedited Reporting defines serious adverse events as follows: a "serious adverse
event” (experience) or reaction is any untoward medical occurrence that at any dose:
results in death, is life-threatening, requires inpatient hospitalisation or prolongation
of existing hospitalisation, results in persistent or significant disability/incapacity, or
is a congenital anomaly/birth defect
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For the purpose of this guideline, "other significant adverse events'' are marked
haematological and other laboratory abnormalities and any adverse events that led to
an intervention, including withdrawal of drug treatment, dose reduction or significant
additional concomitant ther apy.
In the following sections, three kinds of analysis and display are called for:
1) summarised data, often using tables and graphical presentations presented
in the main body o f the report
2) listings of individual patient data, and
3) narrative statements of events of particular' interest.
In all tabulations and analyses, events associated with both test drug and control
treatment should be displayed
12.1

EXTENT OF EXPOSUEE

The extent of exposure to test drugs/investigational products (and to active control
and placebo) should be characterised according to the number of patients exposed, the
duration of exposure, and the dose to which they were exposed
•

Duration:: Duration of exposure to any dose can be expressed as a median or
mean, but it is also helpful to describe the number of patients exposed for1
specified periods of time, such as for one day or' less, 2 days to one week,
mor e than one week- to one month, mor e than one month to 6 months etc.
The numbers exposed to test drug(s)/investigational product(s) for the
various durations should also be broken down into age, sex, and racial
subgroups, and any other pertinent subgroups, such as disease (if more than
one is represented), disease severity, concurr ent illness

•

Dose. The mean or median dose used and the number of patients exposed to
specified daily dose levels should be given; the daily dose levels used could be
the maximum dose for each patient, the dose with longest exposure for each
patient, or the mean daily dose It is often useful to provide combined doseduration information, such as the numbers exposed for a given duration (e.g„,
at least one month) to the most common dose, the highest dose, the
maximum recommended dose etc. In some cases, cumulative dose might be
pertinent. Dosage may be given as the actual daily dose or on a mg/kg or
mg/m2 basis as appropriate. The numbers of patients exposed to various
doses should be broken down into age, sex, and racial subgroups, and any
other pertinent subgroups,

•

Drug concentration: If available, drug concentration data (e,g, concentration
at the time of an event, maximum plasma concentration, area under' curve)
may be helpful in individual patients for1correlation with adverse events or
changes in labor atory variables, (Appendix 16.2.5)
It is assumed that all patients entered into treatment who r eceived at least
one dose of the tr eatment ar e included in the safety analysis; if that is not
so, an explanation should he provided
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12.2

ADVERSE EVENTS (AEs)

12.2.,1 Brief Summary of Adverse Events
The overall adverse event experience in the study should be desciibed in a biief
narrative, supported by the following moie detailed tabulations and analyses, In
these tabulations and analyses, events associated with both the test drug and control
treatment should be displayed
12.2.2 Display of Adverse Events
All adverse events occurring after initiation of study treatments (including events
likely to be related to the underlying disease or likely to represent concomitant
illness, unless there is a prior agreement with the regulatory authority to consider
specified events as disease related) should be displayed in summary tables (section
14.3.1) The tables should include changes in vital signs and any laboratory changes
that were considered serious adverse events or other' significant adverse events.
In most cases, it will also be useful to identify in such tables "treatment emergent
signs and symptoms" (TESS; those not seen at baseline and those that worsened even
if present at baseline),.
The tables should list each adverse event, the number o f patients in each treatment
group In whom the event occurred, and the rate of occurrence When treatments are
cyclical, e g , cancer' chemotherapy, it may also be helpful to list results separately for
each cycle. Adverse events should be grouped by body system Each event may then
be divided into defined severity categories (e g.,, mild, moderate, severe) if these were
used. The tables may also divide the adverse events into those considered at least
possibly related to drug use and those considered not related, or use some other'
causality scheme (e g.., unrelated or possibly, probably, or definitely related). Even
when such a causality assessment is used, the tables should include all adverse
events, whether1or not considered drug related, including events thought to repr esent
inter current illnesses.. Subsequent analyses of the study or1of the overall safety data
base may help to distinguish between adverse events that are, or are not, considered
drug related.. So that it is possible to analyse and evaluate the data in these tables, it
is important to identify each patient having each adverse event,. An example of such a
tabular presentation is shown below
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A dverse E v e n t s: N um ber O bsekved
w it h

R ate,

P a t ie n t I d e n t if ic a t io n s

Tie atme nt Gr oup X

N=50

Related

NR

Total

Seveie

Moderate

Mild

and

Related

NR

Belated*

NR*

6 (12%)

2 (4%)

3 (6%)

1 (2%)

3 (6%)

1 (2%)

N il**
N12
N13
N14
N15
N16

N21
N22

N31
N32
N33

N41

N51
N52
N53

N61

Related

Total
NR

BodySystemA
Event 1

12 (24%)

4 (8%)

Event 2
*NR = not related, related could be expanded, e g , as definite, probable, possible
**Patient identification number
In addition to these complete tables provided in 14.3,1, an additional summary table
comparing treatment and control groups, without the patient identifying numbers
limited to relatively common adverse events (e.g., those in at least 1% of the treated
group), should be piovided in the body of the report
In presenting adverse events, it is important both to display the original terms used
by the investigator* and to attempt to group related events (i.e,, events that probably
represent the same phenomena) so that the true occurrence rate is not obscured,. One
way to do this is with a standard adverse reactionlevents dictionary..
12,2.,3 Analysis of Adverse Events
The basic display of adverse event rates described in section 12 2.2 (and located in
section 14.3 1) of the report, should be used to compare rates in treatment and control
groups. For this analysis it may be helpful to combine the event severity categories
and the causality categories, leading to a simpler side-by-side comparison of
treatment groups. In addition, although this is usually best done in an integrated
analysis of safety, if study size and design permit, it may be useful to examine the
mor e common adverse events that seem to be dr ug related for* relationship to dosage
and to mg/kg or rag/m3 dose, to dose regimen, to duration of treatment, to total dose,
to demographic characteristics such as age, sex, race, to other baseline features such
as renal status, to efficacy outcomes, and to drug concentration. It may also be useful
to examine time of onset and duration of adverse events. A variety of additional
analyses may be suggested by the study results or by the pharmacology of the test
drug/investigational product.
It is not intended that every adverse event be subjected to rigorous statistical
evaluation. It may be apparent from initial display and inspection of the data that a
significant relation to demographic or other baseline features is not present. If the
studies are small and if the number of events is relatively small, it may be sufficient
to limit analyses to a comparison of treatment and control,
22
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Undei certain circumstances, Hfe table or similar analyses may be more informative
than reporting of crude adverse event rates. When, treatments are cyclical, eg-,
cancer chemotherapy, it may also be helpful to analyse results separately for each
cycle
12,2.4 Listing of Adverse Events by Patient
All adverse events for each patient, including the same event on several occasions
should be listed in appendix 16 2.7, giving both preferred term and the original term
used by the investigator The listing should be by investigator and by treatment
group and should include:
- Patient identifier1
- Age, race, sex, weight (height, if relevant)
- Location o f CRFs, if provided
- The adverse event (preferred term, reported term)
- Duration of the adverse event
-

Severity (e g , mild, moderate, severe)

- Seriousness (serious/non-serious)
- Action taken (none, dose reduced, treatment stopped, specific treatment
instituted etc.)
-

Outcome (e g., CIOMS format)

-

Causality assessment (e g., related/not related)
should be described in the table or elsewhere

How this was determined

- Date of onset or date of clinic visit at which the event was discovered
-

Timing of onset of the adverse event in relation to last dose o f test
drug/investigational pr oduct (when applicable)

~ Study treatment at time of event or most recent study tr eatment taken
~ Test drug/investigational product dose in absolute amount, mg/kg or1mg/m2 at
time of event
-

Drug concentr ation (if known)

- Duration o f test drug/investigational product treatment
- Concomitant treatment during study.
Any abbreviations and codes should be clearly explained at the beginning of the
listing or, preferably, on each page,
12.3

DEATHS, OTHER SERIOUS ADVERSE EVENTS, AND OTHER
SIGNIFICANT ADVERSE EVENTS
Deaths, other serious adverse events, and other significant adverse events deserve
special attention,
12.3.1 Listing of Deaths, other Serious Adver se Events and Other Significant
Adverse Events
Listings, containing the same infor mation as called for in section 12,2.4 above, should
be provided for the following events.
12.3.1.1

Deaths
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All deaths duiing the study, including the post treatment follow-up period, and deaths
that resulted from a process that began duiing the study, should be listed by patient
in section 14,3 2.
12..3..1,2

Other Serious Adverse Events

All serious adverse events (other than death but including the seiious adverse events
temporally associated with or preceding the deaths) should be listed in section 14.3,2,
The listing should include laboratory abnormalities, abnormal vital signs and
abnormal physical observations that were considered serious adverse events.
12.3.1.3
Other Significant Adverse Events
Marked haematological and other' laboratory abnormalities (other than those meeting
the definition of seiious) and any events that led to an intervention, including
withdrawal of test drug/investigational product treatment, dose reduction, or
significant additional concomitant therapy, other than those reported as seiious
adverse events, should be Hated in section 14 .3 ,2.
12.3

.2 Narratives of Deaths, Other Seiious Adverse Events and Certain
Other Significant Adverse Events
There should be brief narratives describing each death, each other seiious adverse
event, and those of the other significant adverse events that are judged to be of special
interest because of clinical importance These narratives can be placed either in the
text of the report or in section 14.3 3, depending on their number Events that were
clearly unrelated to the test drug/investigational product may be omitted or1described
very briefly. In general, the narrative should describe the following:
the nature and intensity of event, the clinical course leading up to event, with an
indication of timing r elevant to test dr ug/investigational product administr ation;
relevant laboratory measurements, whether the drug was stopped, and when;
countermeasures; post mortem findings; investigator's opinion on causality, and
sponsor's opinion on causality, if appropriate.
In addition, the following information should be included:
- Patient identifier'
- Age and sex ofpatient; general clinical condition of patient, if appropriate
- Disease being treated (if the same for all patients this is not required) with
duration (of current episode) of'illness
- Relevant concomitant/pr evious illnesses with details of occunence/duration
-

Relevant concomitant/pr evious medication with details of dosage

-

Test drug/investigational product administered, drug dose, if this varied
among patients, and length of time administer ed .

12 .3. 3 Analysis and Discussion of Deaths, Other1Serious Adverse Events and
Other Significant Adverse Events
The significance of the deaths, other seiious adverse events and other' significant
adverse events leading to withdrawal, dose reduction or institution of concomitant
therapy should be assessed with respect to the safety of the test drug/investigational
product. Particular attention should be paid to whether any of these events may
represent a previously unsuspected important adverse effect of the test
drug/investigational product. For seiious adverse events that appear of'particular
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importance, it may be useful to use life table or similar analyses to show their relation
to time on test drug/investigational pioduct. and to assess their risk over time.
12.4

CLINICAL LABORATORY EVALUATION

12,4,1 Listing of Individual Labor atory Measurements by Patient (16.28) and
Each Abnormal Laboratory Value (14,3.4)
When required by regulatory authorities, the results of all safety-related laboratory
tests should be available in tabular listings, using a display similar' to the following,
where each row represents a patient visit at which a laboratory study was done, with
patients grouped by investigator (if more than one) and treatment group, and columns
include critical demographic data, drug dose data, and the results of the laboratory
tests, As not all tests can be displayed in a single table, they should be grouped
logically (haematological tests, liver1 chemistries, electrolytes, urinalysis etc.).
Abnormal values should be identified, e.g„, by underlining, bracketing etc. These
listings should be submitted as part of the registration/marketing application, when
this is required, or may be available on request..
L is t

of

L a b o r a t o r y M e a su r e m e n t s
Laboratory Tests

Patient

Time

Age

Sox

Race

Weight

Dose

SCO T

SGPT

AP........X

#1

TO

70

M

W

70 kg

400mg

VI*

V5

V9

V2

V6

V10

T1

#2

T2

V3

V7

V ll

T3

V4

V8

V12

V13

V16

V19

T21

V14

V17

V20

T32

V15

V18

V21

T10

65

F

B

50 kg

300mg

* Vn = value of a particular test
For1 all regulatory authorities, there should be a by-patient listing of all abnormal
laboratory values in section 14 3 4, using the format described above. For laboratory
abnormalities of special interest (abnormal laboratory values of potential clinical
impor tance), it may also be useful to provide additional data, such as normal values
before and after the abnormal value, and values o f related laboratory tests In some
cases, it may be desirable to exclude certain abnormal values from further analysis.
For example, single, non-replicated, small abnormalities of some tests (e g., uric acid
or electrolytes) or occasional low values of some tests (e.g., transaminase, alkaline
phosphatase, BUN etc.) can probably be defined as clinically insignificant and
excluded. Any such decisions should he clearly explained, however1, and the complete
list of values provided (or available to authorities on request) should identify every
abnormal value.
12. 4.2 Evaluation of Each Labor atory Par ameter
The necessary evaluation of laboratory values must in part be determined by the
results seen, but, in general, the following analyses should be provided. For1 each
analysis, comparison of the treatment and control groups should be carried out, as
appropriate, and as compatible with study size.. In addition, normal laboratory ranges
should be given for each analysis
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12,4,2,1 Laboratory Values Over Time
For each parameter at each time over the course of the study (e g., at each visit) the
following should be described: the group mean or median values, the range of values,
and the number ofpatients with abnormal values, or with abnormal values that are of
a certain size (e.g, twice the upper limit of normal, 5 times the upper limit; choices
should he explained) Graphs may be used
12«4.2.,2 Individual Patient Changes
An analysis of individual patient changes by treatment group should be given. A
variety of appr oaches may be used, including:
" I.

"Shift tables" - These tables show the number ofpatients who are low, normal, or
high at baseline and then at selected time intervals

II. Tables showing the number or fraction ofpatients who had a change in parameter
of a predetermined size at selected time intervals . For example, for BUN, it might
be decided that a change of more than 10 mg/dL BUN should be noted. For this
parameter, the number ofpatients having a change less than this or greater than
this would be shown for one or more visits, usually grouping patients separately
depending on baseline BUN (normal or elevated).. The possible advantage of this
display, compared to the usual shift table, is that changes of a certain size are
noted, even if the final value is not abnormal.
III. A graph comparing the initial value and the on-treatment values of a laboratory
measur ement for each patient by locating the point defined by the initial value on
the abscissa and a subsequent value on the ordinate. If no changes occur, the
point representing each patient will be located on the 45° line A general shift to
higher values will show a clustering of points above the 45° line.. As this display
usually shows only a single time point for' a single treatment, interpretation
requires a time series o f these plots for treatment and control groups.
Alternatively the display could show baseline and most extreme on-fcreatment
value These displays identify outliers readily (it is useful to include patient
identifier s for the outliers).
12,4.,2,3 Individual Clinically Significant Abnormalities
Clinically significant changes (defined by the applicant) should be discussed. A
narrative of each patient whose laboratory abnormality was considered a serious
adverse event and, in certain cases, considered an other significant adverse event,
should he provided under sections 12.3,2 or 14..3.3. When toxicity grading scales are
used (e.g., WHO, NCI), changes graded as severe should be discussed regardless of
seriousness. An analysis of the clinically significant changes, together with a
recapitulation of discontinuations due to laboratory measurements, should be
provided for' each parameter'. The significance of the changes and likely relation to
the treatment should be assessed, e g,, by analysis of such features as relationship to
dose, relationship to drug concentration, disappearance on continued therapy, positive
dechallenge, positive rechallenge, and the nature of concomitant therapy
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12.5

VITAL SIGNS, PHYSICAL FINDINGS AND OTHER OBSERVATIONS
RELATED TO SAFETY
Vital signs, other physical findings, and other' observations related to safety should be
analysed and presented in a way similar to laboratory variables. If there is evidence
of a drug effect, any dose-response or drug concentration-response relationship or
relationship to patient variables (e..g.., disease, demographics, concomitant therapy)
should be identified and the clinical relevance of the observation described
Particular attention should he given to changes not evaluated as efficacy variables
and to those considered to be adverse events.
12.. 6 SAFETY CONCLUSIONS
The over all safety evaluation of the test drug(s)/investigational produces) should be
reviewed, with particular attention to events resulting in changes of dose or need for
concomitant medication, serious adverse events, events resulting in Withdrawal, and
deaths,. Any patients or patient groups at increased risk should be identified and
particular attention paid to potentially vulnerable patients who may be present in
small numbers, e..g., children, pregnant women, frail elderly, people with marked
abnormalities of drug metabolism or excretion etc. The implication of the safety
evaluation for the possible uses of the drug should be described,
13..
DISCUSSION AND OVERALL CONCLUSIONS
The efficacy and safety r esults of the study and the r elationship of r isks and benefit
should be briefly summarised and discussed, referring to the tables, figures, and
sections above as needed The presentation should not simply repeat the description
of results nor1introduce new results
The discussion and conclusions should clearly identify any new or unexpected
findings, comment on their significance and discuss any potential problems such as
inconsistencies between related measures. The clinical relevance and importance of
the results should also be discussed in the light of other' existing data. Any specific
benefits or' special precautions required for individual subjects or1at-risk groups and
any implications for1the conduct of future studies should be identified, Alternatively,
such discussions may be reserved for summaries of safety and efficacy referring to the
entire dossier1(integi ated summaries)
14.

TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT
INCLUDED IN THE TEXT
Figures should be used to visually summarise the important results, or to clarify
results that are not easily understood from tables.
Important demographic, efficacy and safety data should be presented in summary
figures oi' tables in the text of the report. However, if these become obtrusive because
of size or number they should be presented here, cross-referenced to the text, along
with supportive, or additional, figures, tables or listings,
The following information may be presented in this section of the core clinical study
report:
14,1

DEMOGRAPHIC DATA

Summary figures and tables
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14,2

EFFICACY DATA

Summary figures and tables
143 SAFETY DATA
Summary figures and tables
14 .3.1 Displays of Adverse Events
14 .3 .2 Listings of Deaths, Other Serious and Significant Adverse Events
14.3.3 Narratives of Deaths, Other1Serious and Certain Other1Significant Adverse
Events
14.3 4 Abnormal Laboratory Value Listing (Each Patient)
15.
REFERENCE LIST
A list of articles from the literature pertinent to the evaluation o f the study should be
provided
Copies of important publications should be attached in an appendix
(16.1.11 and 16,1.12).
References should be given in accordance with the
internationally accepted standards of the 1979 Vancouver Declaration on "Uniform
Requirements for Manuscripts Submitted to Biomedical Journals" or the system used
in "Chemical Abstracts"
16,
APPENDICES
This section should be prefaced by a full list of all appendices available for the study
report.
Where permitted by the regulatory authority, some of the following
appendices need not be submitted with the r eport but need to be provided only on
request,
The applicant should therefore clearly indicate those appendices that are submitted
with the report.
N.B In order to have appendices available on request, they should be finalised by the
time of filing of the submission.
16.1

STUDY INFORMATION

16 11 Protocol and protocol amendments
16.1.2 Sample case report form (unique pages only)
16.1.3 List of IECs or IRBs (plus the name of the committee Chair1if requir ed by the
r egulatory authority) - Repr esentative wr itten information for patient and
sample consent forms
16.1.4 List and description of investigators and other important participants in the
study, including brief (1 page) CVs or equivalent summaries of training, and
experience relevant to the per formance of the clinical study
16.1 5 Signatures of principal or coordinating investigator^) or sponsor’s responsible
medical officer, depending on the regulatory authority's requirement
16.1.6 Listing o f patients receiving test drug(s)/investxgational product(s) from
specific batches, wher e more than one batch was used
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16.1 7 Randomisation scheme and codes (patient identification and treatment
assigned)
16.1.8 Audit ceitificates (if available) (see Annex IVa and IVb of the guideline)
18.1.9 Documentation of statistical methods
16.1.10 Documentation of inter-laboratory standardisation methods and quality
assmance procedur es if used
16 1.11 Publications based on the study
16.1 12 Impoitant publications referenced in the report
16,2,

PATIENT DATA LISTINGS

16.2.1 Discontinued patients
16.2.2 Protocol deviations
16.2.3 Patients excluded horn the efficacy analysis
16 2. 4 Demogr aphic data
16 2.5 Compliance and/or drug concentration data (if available)
16.2 6 Individual efficacy response data
16.2 7 Adverse event listings (each patient)
16.2.8. Listing of individual laboratory measurements by patient, when required by
r egulatory author ities
10.3

CASE REPORT FORMS

16.3 1 CRFs for deaths, other serious adverse events and withdrawals for AE
16..3..2 Other CRFs submitted
16.4.

INDIVIDUAL PATIENT DATA LISTINGS (US ARCHIVAL LISTINGS)
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ANNEX I

SYNOPSIS
Name of Sp onsor /C ompany :

Name of Finished Product:

Name of Active Ingredient:

Individual Study Table
Referring to Part
of the Dossier
Volume:

Page:

Title of Study:

Investigators:

Study cent re(a):

Publication (reference):

Studied period (years):
(date of first enrolment)
(date of last completed)

Phase of'development:

Objectives:

Methodology:

Number of patients (planned and analysed):

Diagnosis and main criteria for inclusion:

Test product dose and mode of administration, batch number:

Duration of treatment:

Reference therapy, dose and mode of administration, batch number;
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AN NEX 1 coni.
Name of Sponsor /Company:

Name of Finished Product:

Name of Active Ingredient:

Individual Study Table
Referring to Part
of the Dossier

Volume:
Page:

Criteria foi1evaluation:
Efficacy:

Safety:

Statistical methods:

SUMMARY - CONCLUSIONS
E F F I C A C Y R ES U LT S :

S A FE T Y RESU LTS:

CO NCLU SIO N :

Date of the repor t:
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ANNEX II

PRINCIPAL OK COORDINATING
INYESTIGATOR(S) SIGNATURES)
OR SPONSOR’S RESPONSIBLE MEDICAL OFFICER

STUDY TITLE:

.................................... ................. ; ..................

STUDY AUTHOR(S):

..............................................................................

I have read this report and confirm that to the best of my knowledge it accurately
describes the conduct and results of the study

INVESTIGATOR: _______________________ SIGNATURE(S)_____________________
OR SPONSOR’S RESPONSIBLE
MEDICAL OFFICER

AFFILIATION:

DATE:
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ANNEX III a

S t u d y D e s ig n

TREATMENT PERIOD

and

S chedule

of

A s se ssm e n ts

G

B

A

B1

Cl

B2

Test Di ug/
Investigational
Product A
5 mg’

10 m g

^

Run-in
Test Drug/
Investigational
Product B
5 mg

10 mg

/

v
A

C2

Test Drug/
Investigational
Product A
'

5 mg

10 m g

Test Drug/
Investigational
\ Product B
5 mg

10 m g

W eeks

-2 (-3)

0

3

6

9

12

Visit

1

2

3

4

5

6

X2

X

X

X

X

Exercise test 24 h

X1

Medical history

X

Physical examination

X

X

ECG

X

X

Lab,, invest

X

X

Adver se events

X

1 = 14-20 days after visit 1
2 ~ 1-7 days after the first exercise test
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ANNEX III b

Stu

d y

D

es ig n a n d

S

A

c h ed u le o f

ssessm en ts

Double-blind
placebo

0

A ssessm en t

Sci e e n in g

Study Week

-2

Informed consent

X

History

X

Physical exam

X

R u n -in

-1

7

8

9

T rea tm en t

B a s e lin e

0

6

X

2

3

F o llo w -u p

4

5

6

8

X

Effectiveness:
Primary variable

X

X

X

X

Secondary variable

X

X

X

X

Adverse events

X

X

X

X

Lab tests

X

X

X

Body weight

X

X

X

X

x

X

X

X

X

X

X

X

X

X

X

Safety:
X

X
X

X

X

X
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ANNEX IV a
D is p o s it io n

of

P a t ie n t s

N=1,S61
PATIENTS COMPLETING STUDY
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D is p o s it io n

of

A N N EXIVb

P a t ie n t s
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ANNEX V

STUDY#
(Data Set Identification)

L is t in g

of

Pa t ie n t s

who

D is c o n t in u e d T h e r a p y

Centre:
Treatment

Patient#

Sex

Age

Last
Visit

Duration

Dose

Concomitant
Medication

Reason foi_
Discontin.
Adverse
reaction*

Test Diug/
investigational
product

Therapy
failure

Treatment

Patient #

Sex

Age

Last
Visit

Duration

Dose

Concomitant.
Medication

Reason for.
Discontln.

Patient #

Sex

Age

Last
Visit

Duration

Dose

Concomitant.
Medication

Reason for
Discontin.

Active Control^
Comparator

Treatment
Placebo

*The specific reaction leading to discontinuation

(Repeat for other centres)
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ANNEX VI

STUDY#
(Data Set Identification)

L is t in g o f P a t ie n t s a n d O b s e r v a t io n s E xc lu d e d
fr o m E f f ic a c y A n a l ysis
Centre
Treatment

Patient #

Sex

Age

Observation Excluded

Reasonfs)

Sex

Age

Observation Excluded

Reasonfs)

Sex

Age

Observation Excluded

Reasonfs)

Test Diug/Investigational Product

Treatment

Patient #

Active Dr ug/Comp ai afcor

Treatment

Patient #

Placebo

(Repeat for other centres)

Reference Tables
Summary
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ANNEX VII

STUDY#
(Data Set Identification)

N u m b e r of P a t ie n t s E x c l u d e d f r o m E f f ic a c y A n alysis

Test Drug/Investigational Product

NWeek

Reason

1

2

4

Total

Similar tables should be pi epared for the other treatment groups.
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ANNEX VIII

Guidance foe Section 11, 4,,2 - Statistical/A nalytical Issues and
A ppendix 16.1,9
A,

Statistical Considerations
Details of the statistical analysis performed on each primary efficacy variable
should he presented in an appendix,. Details reported should include at least the
following information:
a) The statistical model underlying the analysis. This should be presented
precisely and completely, using references if necessary,
b) A statement of the clinical claim tested in precise statistical terms, eg,, in
terms of null and alternative hypotheses.
c) The statistical methods applied to estimate effects, construct confidence
intervals etc. Literatur e references should be included where appropriate
d) The assumptions underlying the statistical methods. It should be shown,
insofar as statistically reasonable, that the data satisfy crucial assumptions,
especially when necessary to confirm the validity of an inference. When
extensive statistical analyses have been performed by the applicant, it is
essential to consider' the extent to which the analyses wer e planned prior' to
the availability o f data and, if they were not, how bias was avoided in
choosing the particular analysis used as a basis for conclusions. This is
particularly important in the ease of any subgroup analyses, because if such
analyses are not preplanned they will ordinarily not provide an adequate
basis for definitive conclusions.
(i) In the event data transformation was performed, a rationale for the choice
of data transformation along with interpretation of the estimates of
treatment effects based on transformed data should be provided
(if) A discussion of the appropriateness of the choice of statistical procedure
and the validity of statistical conclusions will guide the regulatory
authority's statistical reviewer in determining whether reanalysis of data
is needed.
e) The test statistic, the sampling distribution of the test statistic under1the
null hypothesis, the value of the test statistic, significance level (i.e , pvalue), and intermediate summary data, in a format that enables the
regulatory authority's statistical reviewer1to verify the results of the analysis
quickly and easily. The p-values should be designated as one- or two-tailed.
The rationale for using a one-tailed test should be pr ovided..
For example, the documentation of a two-sample t-test should consist of the
value of the t-statistic, the associated degrees of freedom, the p-value, the
two sample sizes, mean and variance for each of the samples, and the pooled
estimate of variance. The documentation of multi-centre studies analysed hy
analysis of variance techniques should include, at a minimum, an analysis of
variance table with terms for centres, treatments, their' interaction, error ,
and total.
For crossover1 designs, the documentation should include
information regarding sequences, patients within sequences, baselines at the
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statt of each period, washouts and length of washouts, dropouts during each
period, treatments, periods, treatment by period interaction, error, and total.
For each source of variation, aside from the total, the table should contain
the degrees o f freedom, the sum of squares, the mean square, the
appropriate F-test, the p-value, and the expected mean square
Intermediate summary data should display the demographic data and
response data, averaged or otherwise summarised, for, each centre-bytreatment combination (or other1design characteristic such as sequence) at
each observation time.
B.

Format and Specifications for Submission of Data Requested, by
Regulatory Authority's Statistical Reviewers
In the report of each controlled clinical study, there should be data listings
(tabulations) of patient data utilised by the sponsor1for statistical analyses and
tables supporting conclusions and major findings. These data listings are
necessary for the regulatory authority’s statistical review, and the sponsor may
be ashed to supply these patient data listings in a computer-readable form.
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WHO | Trial Registr ation Data Set

World Health
Organization
Trial Registration Data Set
Introduction
The Registry Platform has finalized the Trial Registration Data Set. In order to register a trial, Responsible
Registrants must complete Items #3 to #20 for submission to a Primary or Associate Register The previous list o f 20
items will be acceptable for registration until further notice The WHO encourages all registers to transition to the
new data set as soon as possible.
The "form" on the next page is just an example to illustrate the data values, and is NOT an interface for submitting
data to the WHO o r to any register. Actual register submission interfaces will be differ ent from this illustr ation
All entries can be in free text (i e , do not have to be terms from a controlled vocabulary), although some registers
may require or encourage coded entries. The Registry Platform is considering MeSH as the common vocabulary for
any coding o f register entries
Please note that this Data Set applies only to interventional trials.

Registration Data Set (Version 1,0)
This WHO Trial Registration Data Set is now finalized Specific implementation details remain to be resolved and
will be codified in a guidance document that is being developed (e..g.., specific pick list options, whether* age criteria
will be collected in structured form, etc). The “ field value” column given below is just an example to illustrate the
data fields, and does not reflect an actual interface for* submitting data to the WHO or to any register. This Data Set
will be reviewed in 2 years.
For a trial to he properly register ed, all items must he recorded as applicable in a Primary Register.. All entries should
accurately reflect the study protocol. Entries can be in free text (i.e., do not have to be terms from a controlled
vocabulary), although some registers may requir e or* encourage coded entries. The Registry Platform is considering
MeSH as the common vocabulary for coding Conditions, Interventions, and Primary Outcomes.

Item

Definition/Bxplanation

Field Value

... isnj
1

Marne of Primary Register, and the unique ID
number assigned by the Primary Register to
this trial.

Primary Register
and Trial ID #
Trial ID#|

2

3

Date of Registration
in Primary Register I

Secondary ID#s

___
Source(s) of

3

!

HI

s i

Date when trial was officially registered in the
Primary Register YYYY/MM/DD.

Other identifying numbers and issuing
Issuing Authority j____________ j authorities besides the Primary Register, if
any. Include the sponsor name and sponsorissued trial number (e..g,, protocol number) if
ID Number |___________ ,____
available. Also include other trial registers
that have issued an ID number to this trial
There is no limit on the number of Secondary
Click to add more ..
ID numbers that can be provided.
Major source(s) of monetary or material

EXHIBIT

2
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Monetary or Materia
Marne j
Support

support for the trial (e.g., funding agency,
foundation, company).

I

Click to add more.*.

5

Primary Sponsor

Name j

The individual, organization, group or other
legal person taking responsibility for securing
the arrangements to initiate and/or manage a
study {including arrangements to ensure that
the study design meets appropriate standards
and to ensure appropriate conduct and
reporting). In commercial trials, the primary
sponsor is normally the main applicant for
regulatory authorization to begin the study. It ,
may or may not be the main funder.
|

_______ j

Additional individuals, organizations or other
legal persons, if any, that have agreed with
the primary sponsor to take on
responsibilities of sponsorship,
A secondary sponsor may have agreed

6

Secondary Sponsor
(8)

N a m e _ ____ __

• to take on all the responsibilities of
sponsorship jointly with the primary
sponsor; or
• to form a group with the primary
sponsor in which the responsibilities of
sponsorship are allocated among the
members of the group; or
• to act as the sponsor’s legal
representative in relation to some or ail
of the trial sites; or
• to take responsibility for the accuracy
of trial registration information
submitted.

j

Click to add more...

Email, telephone number, or address
7

Contact for Public
Queries
—
Email, telephone number, or address

8

Contact for
Scientific Queries

1---------------—

....

Affiliation |___________
9

Public Title

j

___________ _________ :

Email address, telephone number, or postal
address of the contact who will respond to
general queries, including information about
current recruitment status
Email address, telephone number, or postal
address, and affiliation of the person to
contact for scientific queries about the trial
(e.g.,, principal investigator, medical director
employed by the sponsor). For a multi-center
study, enter the contact information for the
lead Principal Investigator or overall scientific
director.
Title intended for the lay public in easily
understood language.
Scientific title of the study as it appears in the
protocol submitted for funding and ethical
review, include trial acronym if available.

10 Scientific Title
Acronym __________________J
11

Countries of
Recruitment

------- --- —--------------

The countries from which participants will be,
are intended to be, or have been recruited.
Primary health condition(s) or problem(s)
studied (e g., depression, breast cancer,
medication error), !f the study is conducted in

„,1---- -------------------- / J _ J . _

1> 1
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Health Condltion(s)
12 or Problem(s)
Studied

Page 3 o f 5

healthy human volunteers belonging to the
target population of the intervention (e.g,
preventative or screening interventions),
enter the particular health condition(s) or
problem(s) being prevented. If the study is
conducted in healthy human volunteers not
belonging to the target population (e g , a
preliminary safety study), an appropriate
keyword will be defined for users to select.

\

,

Enter the specific name of the intervention(s)
and the comparator/contro!(s) being studied.
Use the International Non-Proprietary Name
if possible (not brand/trade names). For an
unregistered drug, the generic name,
chemical name, or company serial number is
acceptable. If the intervention consists of
several separate treatments, list them all in
one line separated by commas (e.g,, "low-fat
diet, exercise").

intervention name(s)

Other details (e.g., dose, duration,
etc.) \_________ ______ J

13 Intervention (s)

Click to add more experimental
interventions .
Control intervention name
i
Other details of control (e.g., dose,
duration, etc.J,______ ______ __. j

The control intervention(s) is/are the
interventions against which the study
intervention is evaluated (e.g, placebo, no
treatment, active control). If an active control
is used, be sure to enter in the name(s) of
that intervention, or enter "placebo" or "no
treatment" as applicable.

For each intervention, describe other
Click to add more control interventions . intervention details as applicable (dose,
duration, mode of administration, etc)
Inclusion and exclusion criteria for participant
selection, including age and sex.

Inclusion Criteria

Key Inclusion and

L _________ _______I

Exclusion Criteria

Exclusion

14

Criteria!___ _____________ .

15 Study Type

16 Date of First
Enrollment

¡jj

[Choose one

A single arm study is one in which all
participants are given the same intervention
Trials in which participants are assigned to
receive one of two or more interventions are
NOT single arm studies. Crossover trials are
NOT single arm studies.
A trial is "randomized" if participants are
assigned to intervention groups using a
method based on chance (e..g,, random
number table, random computer-generated
sequence, minimization, adaptive
randomization).

________

17 Target Sample Size

j

..............
j

a

Anticipated or actual date of enrollment of the
first participant (YYYY/MM).
Number of participants that this trial plans to
enroll.
Recruitment status of this trial.
• Pendina: participants are not vet beinq
recruited or enroiied at any site

1

, _ _ J_ x /_! „ j___ / J _ x _

_ _ j _ l _ , / ___ !
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Active: participants are currently being
recruited and enrolled
Temporary halt: thère is a temporary halt
in recruitment and enrollment
Closed: participants are no longer being
recruited or enrolled

18 Recruitment Status

Outcomes are events, variables, or
experiences that are measured because it is
believed that they may be influenced by the
intervention. The Primary Outcome should be
the outcome used in sample size
calculations, or the main outcome(s) used to
determine the effects of the fntervention(s).

Outcome Name

19 Primary Outcome(s)

Timepoints

Click to add more outcomes

Enter the names of ail primary outcomes in
the trial as well as the pie-specified timepoint
(s) ofprimary interest Be as specific as
possible with the metric used (e.g., "% with
Beck Depression Score > 10 ’’rather than just
"depression") Examples:
Outcome Name: all-cause mortality,
Timepoints: 5 years; or Outcome Name:
Mean Beck Depression Score, Timepoint: 18
weeks
Secondary outcomes are events, variables,
or experiences that are of secondary interest
or that are measured at timepoints of
secondary interest. A secondary outcome
may involve the same event, variable, or
experience as the primary outcome, but
measured at timepoints other than those of
primary interest (e.g.., Primary outcome: all
cause mortality at 6 years; Secondary
outcome: all-cause mortality at 1 year, 3
years), or may involve a different event,
variable, or experience altogether (e.g.,
Primary outcome: all-cause mortality at 5
years; Secondary outcome: hospitalization
rate at 5 years).

Outcome Name

20

Key Secondary
Outcomes

Timepoints

Click to add more outcomes

Enter the name and timepoint(s) for all
secondary outcomes of clinical and/or
scientific importance. Be as specific as
possible with the metric used (e.g,, “% with
Beck Depression Score > 10” rather than just
"depression"). Examples: Outcome Name: allcause mortality, Timepoint: 6 months, 1 year;
or Outcome Name: Mean glycosylated
hemoglobin A1C, Timepoint: 4 and 8 weeks

Non-dr ug Trials Examples
Here are some examples o f non-drug trials which apply the WHO Minimum 20 Items Trial Registration Data Set.
These examples refer to trials dealing with procedures, behavioral treatments, devices» or process-of'-caie changes.

A.

Ì

* À

Early trials (Phase 1 and Phase 2)

rl*i

-t

iA

/ «4 i-%J-.-H

L

x

___ 1
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Non-exhaustive List
1

A randomised controlled trial of'an intervention to improve communication with patients suffering
acute chest pain: click here

2..

The prevention o f developmental arid behavioral problems o f very preterm infants and parental stress
through the use of development care: an intervention program for infants and parents: click here

3.

New Technologies for Cervical Cancer screening: click her e

4

A Randomised Controlled Trial o f goal setting and pacing for cardiac patients not suitable for group
based cardiac rehabilitation: click here

5.

Group Counseling for Smoking Cessation: click here

6.

Cell Repair in Heart failure: click here

7. Phase 1 Study o f the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced
Upper Lobe Predominant Emphysema: click here

B

Phase 3 and above
Non-exhaustive List
1.

feasibility study o f the effect o f price discounts and nutrition education on food purchases in
supermarkets: click here

2

Domiciliary versus centre-based rehabilitation of older community dwellers: Randomised trial with
economic evaluation: click here

3. Cluster-randomised trial o f general practitioners to evaluate the effects o f education versus no specific
education about depression and self-harm behaviour' in later life: click her e
4.. Promoting Physical Activity in Later L ife: Impact on Memory and Mood: click here
5.

The effects of Tea Tree oil on acne: click here

6, House dust mite allergen avoidance and omega 3 fatty acid supplementation to reduce the incidence o f
asthma in children with a family history, dick here

C . Other non-iandomiseil trials
Non-exhaustive List
l . Evaluation o f an interdisciplinary assessment service to evaluate new prosthetic prescriptions for
trauma related trans-femoral amputees: click here
2

Study o f Decision Making in Patients Participating in Phase I Clinical Trials: click here

3.. Evaluating Patient Participation in Phase I Clinical Trials: click here

Employment j Other UN Sites |Search) Suggestions |RSS j Privacy
© World Health Organization 2007. All rights reserved

Tvffrt*/ A

,.i_

/. . t

* ,

.

■
%

Exhibit 3

Multi-State Attorney General Consent Judgment with Bayer Corporation

PUBLIC ACCESS TO SUMMARIES OF B A Y E R CLINICAL
STUDIES ON CLINICAL STUPYRESULTS.ORG
Bayer Corporation announced that Bayer will post on ClinicalStudyResults.org
summaries o f the clinical study reports for all Phase II, III and IV Bayer-sponsored
clinical studies conducted on Bayer’ s drugs.
Access to this information is unrestricted and free-of-charge.
The content o f the
summaries will conform to the principles required by the International Conference on
Harmonization o f Technical Requirements for Registration o f Pharmaceuticals for
Human Use (ICH) Guidelines for Industry; Structure and Content o f Clinical Study
Reports (ICH’ s E-3 Guidance). The content o f the summaries will also conform to the
template published in the Federal Register, Vol. 61, July 17, 1996, Page 37320 ei seq,
Bayer will make all reasonable efforts to post within the next four months, the summaries
o f clinical study reports that were completed since July 1, 2005. Bayer shall, in general,
post the summaries o f clinical studies that are completed in the future within 12 months
o f the study completion date or upon first marketing. In some cases, the timing may be
affected by the policies o f a peer reviewed journal that has accepted an article about the
study.
There may be a delay in posting complete summaries o f clinical study reports because
Bayer may seek intellectual-property protection or comply with policies o f peer-reviewed
journals to which manuscripts have been submitted for publication. Further, Bayer may
be required to withhold certain summaries o f clinical study reports to comply with
confidentiality provisions in agreements with other parties. In regard to confidentiality
agreements, in all future clinical studies, Bayer will use reasonable efforts to exclude
provisions limiting the publication o f summaries o f clinical study reports. For all past
clinical studies with such confidentiality agreements, Bayer will make reasonable efforts
to secure the right to post the summaries o f clinical study reports.
Questions concerning Bayer’ s registry should be directed to: Bayer Clinical
Communications at 800-288-8371.

1

STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET No. C V M -A I.

STATE OF MAINE
Plaintiff,
v.
CONSENT JUDGMENT
BA YER CORPORATION
Defendant.

Plaintiff, State o f Maine, acting by and through Attorney General G. Steven Rowe
has brought this action pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.A. §
205-A

et seq., having filed a complaint against the Defendant, Bayer Corporation.

(“Bayer” ) and the parties having consented to the entry o f this Consent Judgment
(“ hereinafter referred to as “ Consent” ) for the purposes o f settlement only, without this
Consent constituting evidence against or any admission by any party, and without trial o f
any issue o f fact or law, N O W THEREFORE, upon the consent o f the parties hereto IT
IS HEREBY ORDERED, ADJUDGED AND DECREED AS FOLLOWS:
PR E A M B LE
This Consent Judgment is entered into between the Attorneys General or other
entities1 o f the States and Commonwealths o f Arizona, Arkansas, California,
Connecticut, Delaware, Florida, Idaho, Illinois, Iowa, Kansas, Kentucky, Maine,
Maryland, Massachusetts, Michigan, Mississippi, Montana, Nevada, North Carolina,

For the purposes o f this agreement, when the entire group is referred to as
“ Signatory Attorneys General,” such designation, as it pertains to CONNECTICUT, shall
refer to the Commissioner o f the Department o f Consumer Protection, who enters this
Consent pursuant to the Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. Sec.
42-1 lOj, acting by and through his counsel, Richard Blumenthal, Attorney General for
the State o f Connecticut, For M ONTANA, such designation shall refer to the Consumer
Protection Office o f the Department o f Justice who enters into this settlement pursuant to
The Montana Unfair Trade and Consumer Protection Act o f 1973 M CA 30-14-101 et ah,
acting by and through his counsel, Mike McGrath, Attorney General for the State o f
Montana.

Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Vermont,
Virginia, Washington, and Wisconsin (hereinafter referred to as “ Signatory Attorneys
General” ), acting on behalf o f their respective states, and pursuant to their respective
consumer protection statutes; and Bayer Corporation (hereinafter referred to as “ Bayer”).

I.

DEFINITIONS

The following definitions shall be used in construing this Consent:
A.

“ Adverse Events” shall mean an adverse event associated with the use o f a

drug in humans. “ Serious Adverse Events” are those that, at any dose, are fatal, lifethreatening, disabling or incapacitating; result in hospitalization; prolong a hospital stay;
or are associated with congenital abnormality. In addition, any event not meeting the
above criteria may still be deemed Serious i f such an event jeopardizes the patient and
may require medical or surgical intervention to prevent one o f the outcomes listed above.
B.

“ Baycol®” shall mean cerivastatin sodium.

C.

“ Bayer” shall mean the Bayer Corporation and its U.S.-based affiliates,

subsidiaries, predecessors, successors, and assigns.
D.

“ Bayer Website” shall mean Bayer’ s main Internet site, currently

http://www.pharma.baver.com or a link from that site.
E.

“Bayer-Sponsored” shall mean Bayer is responsible for regulatory

approvals, site selection, protocol development, initiation, monitoring, safety reporting,
and Data analysis, even if some or all o f these activities are transferred to another party
(e.g. Clinical Research Organization). A Clinical Study is not “Bayer-Sponsored” i f it is
initiated by a third party for which Bayer provides some support, for example by way o f a
grant or supply o f medication, but with sponsor responsibilities for study initiation and
management agreed in writing to reside with the third party. For purposes o f this
Consent only, studies conducted by Bayer’ s parent entity and its foreign affiliates shall be
considered Bayer-Sponsored.
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F.

“ Clinical Study” shall mean any research project that prospectively

assigns human subjects to intervention and concurrent comparison/control groups to
study the cause-and-effect relationship between a medical intervention and a health
outcome. The term “ Clinical Study” is not limited to a research study that is randomized
or blinded; and is not limited to studies conducted in the United States.
G.

“ Clinical Study Report” shall mean a description o f the Protocol, a

summary o f all the Data, a description and the results o f statistical analyses o f the Data, a
listing o f the common Adverse Events and a more detailed listing o f the Serious Adverse
Events, and the clinically relevant conclusions drawn from the Data in a BayerSponsored Clinical Study, including the answers to the questions posed in the Protocol.
H.

“ Compliance Provisions” shall mean Paragraphs 6 through 16 o f this

Consent.
I.

“ Covered Conduct” shall mean Bayer’ s promotional and marketing

practices regarding the prescription drug Baycol®. .

J.

“ Data” shall mean all o f the results and outcome measurements obtained

from a Clinical Study.

K.

“ Effective Date” shall mean the date by which all Parties have executed

the Consent.
L.

“ Exploratory Phase II Clinical Study” shall mean a study with less than

fifty (50) participants and where a health outcome is not a predefined endpoint o f the
study.
M.

“ Individual State” and “ State” shall mean each Signatory Attorney

General who is participating in the Multistate Working Group.
N.

“Multistate Working Group” (“M SW G ”) shall mean the Attorneys

General and their staffs representing the States and Commonwealths o f Arizona,
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Arkansas, California, Connecticut, Delaware, Florida, Idaho, Illinois, Iowa, Kansas,
Kentucky, Maine, Maryland, Massachusetts, Michigan, Mississippi, Montana, Nevada,
North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee,
Texas, Vermont, Virginia, Washington, and Wisconsin.
O.

"Non-Exploratory Phase II Clinical Study" shall mean a study with fifty

(50) or more participants or where a health outcome is a pre-defmed endpoint o f the
study.
P.

“Parties” shall mean Bayer and the Individual States.

Q.

“ Post” information shall mean to provide access to the information on an

Internet site that provides no-cost and unrestricted access to both the site and the
information Bayer has provided through the site. The Posting obligations exclusively
reside with Bayer as defined in paragraph C, not Bayer’ s parent entity or its foreign
affiliates. Bayer does not fulfill a requirement to Post information under this Consent if it
does so on an Internet site, other than the Bayer Website, that contains any advertisement
by any pharmaceutical company or for any pharmaceutical product.
R.

“ Products” shall mean any pharmaceutical or biological product

manufactured, distributed, sold, marketed or promoted in any way by Bayer, solely or in
conjunction with other companies in the United States.
S.

“ Protocol” shall mean the investigational plan that is used to conduct the

Clinical Study. The Protocol for an acute phase o f a Clinical Study is separate from the
Protocol o f a continuation or extension phase o f a Clinical Study.
T.

“ Signatory Attorney General” shall mean the Attorney General, or his or

her designee, o f each state in the Multistate Working Group investigating Bayer’ s
promotion and marketing practices regarding Baycol.®
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U.

“ State Consumer Protection Laws” shall mean the consumer protection

laws under which the Signatory Attorneys General have conducted their investigation.
V.

“ Subject Matter o f this Consent” shall mean the Signatory Attorneys5

General investigation under the State Consumer Protection Laws o f Bayer5s promotional
and marketing practices regarding the prescription drug Bay col®.
W.

“ Study Completion Date” shall mean the date on which the last

observation is made either o f the last patient who remains enrolled in the ClinicafStudy
or following a decision to terminate the Clinical Study early, whichever happens first.

AR IZO N A Consumer Fraud Act, Ariz. Rev. Stat. §44-1521, et. seq.];
ARKAN SAS - Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101 et seq.;
CALIFORNIA Business and Professions Code § 17200 etseq 17500 et seq ;
CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. §42-110 et
seq.; DELAW ARE - Consumer Fraud Act, 6 Del.C. Section 2511, et seq., UDTPA, 6
Del.C. Section 2531, et seq.; FLORIDA - Deceptive and Unfair Trade Practices Act, Fla.
Stat. Ch. 501.201 et seq.; IDAHO - Consumer Protection Act, Idaho Code § 48-601 et
seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815 ILCS §
505/1 et seq. (2002); IO W A - Iowa Consumer Fraud Act, Iowa Code Section 714.16;
KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623, et seq.; KENTUCKY Consumer Protection Statute, KRS 367.170; MAINE - Unfair Trade Practices Act, 5
M .R.S.A, section 205-A etseq.; M AR YLAN D - Consumer Protection Act, Maryland
Commercial Law Code Annotated § 13-101 et seq.; MASSACHUSETTS - Consumer
Protection Act, M.G.L. c. 93A et seq.; MICHIGAN - Consumer Protection Act, Mich.
Comp. Laws §445.901 etseq. (2004); MISSISSIPPI - Consumer Protection Act, Miss.
Code Ann. § 75-24-1 etseq.; M ON TAN A - Mont. Code Ann. § 30-14-101 etseq.;
N E V A D A - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NORTH CAROLINA - Unfair and Deceptive Trade Practices Act, N.C.G.S. § 75-1.1 et
seq.; OHIO - Consumer Sales Practices Act, R.C. § 1345.01 et seq.; OREGON Unlawful Trade Practices Act, ORS 646.605 to 646.656; PENNSYLVANIA - Unfair
Trade Practices and Consumer Protection Law, 73 P.S. § 201-1 etseq.; SOUTH
CAROLINA - Unfair Trade Practices Act, Sections 39-5-10 et seq.; SOUTH D AKOTA Deceptive Trade Practices and Consumer Protection Law, SDCL Chapter 37-24;
TENNESSEE - Consumer Protection Act, Tenn. Code Ann. § 47-18-101 et seq., (1977);
TEXAS - Deceptive Trade Practices and Consumer Protection Act, Tex. Bus. And Com.
Code § 17.41 et seq., (Vernon 2002); VERM ONT - Consumer Fraud Act, 9 V.S.A. §
2451 et seq.; VIRGINIA - Virginia Consumer Protection Act, 59.1 -196 et seq.;
WASHINGTON- Washington Consumer Protection Act - R.C.W. 1986 et seq.;
WISCONSIN - Wis. Stat. § 100.18 (Fraudulent Representations).
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II.
1.

BACKGROUND

Bayer is in the business o f among other things, researching, developing,

manufacturing, distributing, selling, and promoting drugs for use in treating various
illnesses and diseases,
2.

Baycol®, a prescription drug, was approved initially by the FDA in 1997

as safe and effective as an adjunct to diet for the reduction o f elevated total and LDL
cholesterol levels in patients with primary cholesterolemia and mixed dyslipidemia
(Fredrickson Types Ila and lib) when the response to dietary restriction o f saturated fat
and cholesterol and other non-pharmacological measures alone was not adequate. Bayer
voluntarily withdrew Baycol® from the market in August 2001.
3.

The States have concerns that Bayer failed to adequately warn prescribers

and consumers o f potential adverse side effects o f Baycol®, and, in particular, that such
failure violated the States’ Consumer Protection Laws.
4.

Bayer denies that it failed to adequately warn prescribers and consumers

o f potential adverse side effects o f Baycol® and denies that it violated any o f the State
Consumer Protection Laws.
5.

Bayer enters into this Consent for the purpose o f resolving the Signatory

Attorneys’ General investigation into Bayer’ s promotional and marketing practices
regarding Baycol®, arriving at a complete and total settlement and resolution o f any
disagreement as to the matters addressed in this Consent to avoid unnecessary expense,
inconvenience, and uncertainty, without admitting any violation o f law and without
admitting any wrongdoing, and for settlement purposes only,

III.
6.

COMPLIANCE PROVISIONS

Bayer shall comply with all applicable laws and regulations relating to the

marketing, sale and promotion o f its Products. Bayer shall not make any false,
misleading or deceptive representation regarding any o f its Products in violation o f all
applicable laws and regulations.
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7.

Any terms that are not defined above in Section I shall be interpreted to

have the same meaning as they have in the International Conference on Harmonization
o f Technical Requirements for Registration o f Pharmaceuticals for Human Use (ICH)
Guidelines for Industry: Structure and Content o f Clinical Study Reports (July 1996),
which is annexed as Exhibit 1.
8.

Bayer shall register all Non-Exploratory Phase II, and all Phase III and IV

Bayer-Sponsored Clinical Studies on ClinicalTrials.gov in accordance with the
following requirements:
a.

Bayer shall register Non-Exploratory Phase II, and all Phase III
and IV Bayer-Sponsored Clinical Studies on ClinicalTrials.gov at
the time such studies are initiated.

b. At the time o f registration o f a Non-Exploratory Phase II BayerSponsored Clinical Study, Bayer will post 15 o f the 20 data set
items established by the World Health Organization (“ WHO” ),
attached as Exhibit 2, to ClinicalTrials.gov (that is, all data set
items except 10, 13, 17, 19 and 20) and, i f there is a change in
status, update data set 18 in a timely manner.

Bayer will populate

the remaining five WHO data fields either when the Product
reaches Phase III (and a Phase III Bayer-Sponsored Clinical Study
is initiated), or when the Summary o f the Clinical Study Report is
Posted, whichever occurs first. In the event that a NonExploratory Phase II Bayer-Sponsored Clinical Study o f a Bayer
Product that is approved for marketing and is commercially
available in the United States is terminated prior to one or more o f
its endpoints, Bayer will populate the remaining five WHO data
fields no later than 30 days following termination o f the study.
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c.

{

At the time o f registration o f a Phase III or IV Bayer-Sponsored
Clinical Study, Bayer will post all 20 data set items to
ClinicalTrials.gov.

9.

Bayer shall Post on ClinicalStudyResults.org Summaries o f Clinical Study

Reports (“ Summaries o f Clinical Study Reports” ) for all Phase II, III and IV BayerSponsored Clinical Studies o f Bayer Products that are approved for marketing and are
commercially available in the United States. Should a publicly funded website for such
postings become available after the Date o f this Consent, Bayer shall also Post on that
website as well. Such summaries shall conform to ICH E3 principles and to the
template published in the Federal Register, Vol. 61, July 17, 1996, Page 37320
10.

et seq.

For studies initiated after the date o f this Consent, Bayer will also make all

reasonable efforts to encourage the publication of, or in the alternative, secure the right
to Post, Summaries o f Clinical Study Reports in which Bayer had significant
participation but did not sponsor.
11.

The Summaries o f Clinical Study Reports that Bayer Posts shall accurately

reflect the methodology used to conduct the Clinical Study and summaries o f the Data
obtained during the Clinical Study. The Summaries o f Clinical Study Reports that
Bayer Posts shall include not only the generic and brand names o f the Bayer Products,
but also a listing o f all aliases under which the Bayer Products may be known at the time
o f Posting, including the serial numbers, code names and chemical descriptions.
12.

Bayer shall Post the Summaries o f Clinical Study Reports in accordance

with the following time requirements:
a.

With respect to Products approved for marketing and
commercially available in the United States for any indication
prior to the Date o f this Consent
(i)

Studies completed prior to the Date o f this Consent:
Summaries o f Phase II, III and IV Clinical Study Reports

8

and summaries o f any other studies material to a
physician's judgment in relation to prescribing Products in
the United States, with a Study Completion Date that
occurred between July 1, 2005 and the Date o f this Consent
will be posted within 120 days o f the Effective Date o f this
Consent or within twelve months o f the Study Completion
Date, whichever is later.
(ii)

Studies completed after the Date o f Consent: Summaries
o f Clinical Study Reports for Phase II, III and IV Clinical
Studies and summaries o f any other studies material to a
physician’ s j udgment in relation to prescribing Products in
the United States, completed after the Date o f this Consent
will be Posted within twelve months o f the Study
Completion Date

b.

With respect to Products approved for marketing and
commercially available in the United States for an initial
indication after the Date o f this Consent, Summaries o f Clinical
Study Reports and summaries o f any other studies material to a
physician’ s judgment in relation to prescribing Products in the
United States will be posted within twelve months o f the Study
Completion Date or first marketing, whichever is later.

c.

The parties recognize that, in some instances, there may be a
delay in Posting complete Summaries o f Clinical Study Reports
because Bayer must seek intellectual-property protection or
comply with policies o f Peer Reviewed Journals to which
manuscripts have been submitted for publication; and, further,
that Bayer may be required to withhold certain Summaries o f
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Clinical Study Reports to comply with confidentiality provisions
in agreements with other parties.
d.

In regard to confidentiality agreements, in all future Clinical
Studies Bayer will use reasonable efforts to exclude provisions
limiting the publication o f Summaries o f Clinical Study Reports.
For all past Clinical Studies with such confidentiality
agreements, Bayer will make reasonable efforts to secure the
right to Post the Summaries o f Clinical Study Reports.

e.

The Signatory Attorneys General and Bayer do not intend
Bayer’ s determination o f materiality for posting to be admissible
in private litigation or to constitute an admission by Bayer that
the information posted is in fact material to prescribing
decisions,

13.

Bayer shall clearly and conspicuously state on the Home Page o f the

Bayer Website that the Posted information is available at ClinicalTrials.gov and
ClinicalStudyResults.org. and shall prominently feature links to those websites on the
Home Page o f the Bayer Website.
14.

Within two weeks o f the Date o f this Consent, Bayer shall arrange and pay

for the publication o f the advertisement annexed hereto as Exhibit 3 to run in the next
available print and electronic editions (for at least one month on the electronic editions)
o f each o f the following journals: Journal o f the American Medical Association, N ew
England Journal o f Medicine, Annals o f Internal Medicine, Journal o f the American
Board o f Family Practice, Pharmacotherapy, Annals o f Pharmacotherapy, and the
Journal o f Clinical Pharmacology & Therapeutics. Bayer shall arrange and pay for each
o f the advertisements to be placed between the front cover and the first article in each
journal. Letters to the editor do not constitute articles for the purpose o f this paragraph.
Each advertisement must be at least one-half page in size.

10

15.

Nothing in this Consent shall require Bayer to:
a. take an action that is prohibited by the FDCA or any regulation
promulgated thereunder, or by FDA; or
b. fail to take an action that is required by the FDCA or any
regulation promulgated thereunder, or by FDA. Any written or
oral promotional claim subject to this Consent which is the same or
substantially the same as the language prescribed by FDA shall not
constitute a violation o f this Consent.

16.

Bayer shall:
a.

provide a copy o f the Compliance Provisions o f this Consent
Decree to all current employees having direct responsibility for
Posting Clinical Study information; and will make this Consent
Decree accessible on Bayer’ s intranet site to all current
employees having responsibility for marketing and promoting
its Products. (“ Relevant Persons”);

b.

obtain certifications from the Relevant Persons that they have
received and/or reviewed a copy o f the Compliance Provisions
o f this Consent have read them, understand their
responsibilities and duties in accordance therewith, and will
abide by the Compliance Provisions; and

c.

submit to each Signatory Attorney General, on the anniversary
o f the Effective Date o f this Consent, a written affirmation
setting forth Bayer’ s compliance with this paragraph.

IV.

DISBURSEMENT OF PAYMENTS: PAYMENT TO THE STATES
17..

Within thirty (30) days o f the Effective Date o f this Consent, Bayer shall

pay $8,000,000.00 to the States by electronic fund transfer made payable to the Oregon
Attorney General’ s O ffice which shall divide and distribute these funds as designated by
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and in the sole discretion o f the Signatory Attorneys General as part o f the consideration
for the termination o f their respective investigations under the State Consumer
Protection Laws regarding the Subject Matter o f this Consent. Said payment shall be
used by the States as and for attorneys' fees and other costs o f investigation and
litigation, or to be placed in, or applied to, the consumer protection enforcement fund,
consumer education, litigation or local consumer aid fund or revolving fund, used to
defray the costs o f the inquiry leading hereto, or for other uses permitted by state law, at
the sole discretion o f each Signatory Attorney General.

V.

3

GENERAL PROVISIONS

IB.

This Consent shall be governed by the laws o f the above-named states.

19.

This Consent is entered into by the Parties as their own free and voluntary

act and with full knowledge and understanding o f the nature o f the proceedings and the
obligations and duties imposed by this Consent.
20.

Nothing in this Consent constitutes any agreement by the Parties

concerning the characterization o f the amounts paid pursuant to this Consent for
purposes o f the Internal Revenue Code or any state tax laws.
21.

This Consent does not constitute an approval by the Signatory Attorneys

General o f any o f Bayer's business practices, including its promotional or marketing
practices, and Bayer shall make no representation or claim to the contrary,

J
For ARKAN SAS, the money shall be placed in the Arkansas Attorney General’ s
Consumer Education and Enforcement Fund and held in trust for purposes directly
related to Arkansas consumer protection efforts. For California payment will go to the
California Unfair Competition Fund, D ELA W AR E’ S payment will go to the Consumer
Protection Fund. In MASSACHUSETTS, the money shall be deposited into the Local
Consumer Aid Fund pursuant to M.G.L, c. 12, section 11G. In OREGON, the money
shall be deposited to the Consumer Protection and Education Revolving Account
established pursuant to ORS 180.095. In PENNSYLVANIA, funds distributed to the
Pennsylvania O ffice o f Attorney General may be used for costs o f investigation, attorney
fees and for future consumer protection and public protection purposes. For
WASHINGTON state, in lieu o f direct restitution, the funds may be used for recovery o f
costs and fees and consumer education cy pres.

12

22.

This Consent sets forth the entire agreement between the Parties hereto

and supersedes all prior agreements or understandings, whether written or oral, between
the Parties and/or their respective counsel with respect to the subject matter hereof. This
Consent may be amended by written agreement between the Parties, subject to any
further requirements,under an individual Signatory Attorney General’ s state law.
23.

This Consent may be executed in counterparts, and by different signatories

on separate counterparts, each o f which shall be deemed to constitute an original
counterpart hereof, and all o f which shall together constitute one and the same Consent.
One or more counterparts o f this Consent may be delivered by facsimile or electronic
transmission with the intent that it or they shall constitute an original counterpart hereof,
24.

This Consent shall become effective on the Effective Date and Bayer’ s

obligations to Post information and otherwise publish its Clinical Study Reports shall
remain in effect for Ten (10) years following the Effective Date.

VI.
25.

REPRESENTATIONS AND WARRANTIES

Bayer acknowledges that it is a proper party to this Consent. Bayer further

warrants and represents that the individual signing this Consent on behalf o f Bayer is
doing so in his or her official capacity and is fully authorized by Bayer to enter into this
Consentand to legally bind Bayer to all o f the terms and conditions o f the Consent.
26.

Each o f the Parties represents and warrants that it negotiated the terms o f

this Consent in good faith.
27.

Each o f the Signatory Attorneys General warrants and represents that he

or she is signing this Consent in his or her official capacity, and that he or she is fully
authorized by his or her state to enter into this Consent, including but not limited to the
authority to grant the release contained in Paragraphs 29-31 o f this Consent, and to
legally bind his or her state to all o f the terms and conditions o f this Consent.
28.

Bayer acknowledges and agrees that the Signatory Attorneys General have

relied on all o f the representations and warranties set forth in this Consent and that, if
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any representation is proved false, deceptive, misleading, or inaccurate in any material
respect, the Signatory Attorneys General have the right to seek any relief or remedy
afforded by law or equity in their respective states.

VII.
29.

RELEASE

Based upon their investigation into Bayer’ s promotional and marketing

practices regarding Baycol, the Signatory Attorneys General have concluded that this
Consent is the appropriate resolution o f any alleged violations o f the State Consumer
Protection Laws. The Signatory Attorneys General acknowledge by their execution
hereof that this Consent terminates their investigation under the State Consumer
Protection Laws into Bayer’ s promotional practices regarding Baycol® prior to the
Effective Date o f this Consent.
30.

In consideration o f the Compliance Provisions, payments, undertakings

and acknowledgments provided for in this Consent, and conditioned upon Bayer’ s full
payment o f the amount specified in Paragraph 17 and subject to the reservations set forth
in Paragraph 31 by its execution o f this Consent, each Signatory Attorney General, as
defined in Section I, Paragraph T, releases and forever discharges, to the fiillest extent
permitted by law, Bayer and all o f its past and present officers, directors, shareholders,
employees, affiliates,, subsidiaries, affiliates, predecessors, assigns and successors
(hereinafter referred to collectively as the “ Released Parties”), from the following: all
civil claims, causes o f action, counterclaims, set-offs, demands, actions, suits, rights,
liabilities, damages, restitution, fines, costs and penalties under the above-cited statutes
arising from the Covered Conduct, also defined as the Subject Matter o f this Consent in
Section I, Paragraph V, as described in Section II, Paragraph 3 o f the Consent, that were
or could have been asserted against the Released Parties by the Signatory Attorneys
General on or after February 18, 1998. This release does not apply to any conduct
occurring after the Effective Date o f this Consent.
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31.

Notwithstanding any term o f this Consent, specifically reserved and

excluded from the Released Claims as to any entity or person, including Released
Parties, are any and all o f the following:
a. • Any criminal liability that any person or entity, including
Released Parties, has or may have to any or all o f the Signatory
Attorneys General;
b.

Any civil or administrative liability that any person or entity,
including Released Parties, has or may have to any or all o f the
Signatory Attorneys General, under any statute, regulation or
rule not expressly covered by the release in Paragraph 30 above,
including, but not limited to, any and all o f the following claims:
(i)

State or federal antitrust violations;

(ii)

Reporting practices, including “ best price” , “average
wholesale price” or “ wholesale acquisition cost” ;

(iii)

Medicaid violations, including federal Medicaid drug
rebate statute violations, Medicaid fraud or abuse, and/or
kickback violations related to any State's Medicaid
program;

c.

(iv)

State false claims violations; and,

(v)

Claims to enforce the terms and conditions o f this Consent.

Any liability under the above-cited consumer protection laws o f
any or all o f the Signatory Attorneys General which any person
or entity, including Released Parties, has or may have to
individual consumers or State program payors o f said Individual
States, and which have not been specifically enumerated as
included herein.
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VIII. NO ADMISSION OF LIABILITY
32.

This Consent does not constitute an admission by Bayer for any purpose,

o f any fact or o f a violation o f any state law, rule, or regulation, nor does this Consent
constitute evidence o f any liability, fault, or wrongdoing. Bayer enters into this Consent
for the purpose o f resolving the concerns o f the Signatory Attorneys General regarding
Bayer's promotional and marketing practices for Baycol®. Bayer does not admit any
violation o f the State Consumer Protection Laws, and does not admit any wrongdoing
that could have been alleged by the Signatory Attorneys General.
33.

This Consent shall not be construed or used as a waiver or any limitation

o f any defense otherwise available to Bayer. This Consent is made without trial or
adjudication o f any issue o f fact or law or finding o f liability o f any kind. Nothing in
this Consent, including this paragraph, shall be construed to limit or to restrict Bayer's
right to use this Consent to assert and maintain the defenses o f res judicata, collateral
estoppel, payment, compromise and settlement, accord and satisfaction, or any other
legal or equitable defenses in any pending or future legal or administrative action or
proceeding.

IX.
34.

DISPUTES REGARDING COMPLIANCE

For the purposes o f resolving disputes with respect to compliance with this

Consent, should any o f the Signatory Attorneys General have cause to believe that Bayer
has violated a provision o f this Consent subsequent to the Effective Date o f this
Consent, then such Attorney General shall notify Bayer in writing o f the specific
objection, identify with particularity the provisions o f this Consent and/or the State
Consumer Protection Law that the practice appears to violate, and give Bayer thirty (30)
business days to respond to the notification; provided, however, that a Signatory
Attorney General may take any action where the Signatory Attorney General concludes
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that, because o f the specific practice, a threat to the health or safety o f the public
requires immediate action.
35.

Upon giving Bayer thirty (30) business days to respond to the notification

described in Paragraph 34 above, the Signatory Attorney General shall be permitted to
serve a document request for relevant, non-privileged, non-work-product records and
documents in the possession, custody or control o f Bayer that relate to Bayer's
compliance with each provision o f this Consent as to which legally sufficient cause has
been shown. In response to that document request,'Bayer will make responsive
documents available to the Signatory Attorneys General.±

X.
36.

PENALTIES FOR FAILURE TO COMPLY

The State may assert any claim that Bayer has violated this Consent in a

separate civil action to enforce this Consent, or to seek any other relief afforded by law.
In any such action or proceeding, relevant evidence o f conduct that occurred before the
Effective Date shall be admissible on any material issue, including alleged willfulness,
intent, knowledge, contempt or breach, to the extent permitted by law.

Bayer does not

waive any objection it may have to the admissibility o f any such evidence, as permitted
by law.

XI.
37.

COMPLIANCE WITH ALL LAWS

Except as expressly provided in this Consent, nothing in this Consent shall

be construed as:
a. relieving Bayer o f its obligation to comply with all applicab!e=state
laws, regulations or rules, or granting permission to engage in any
acts or practices prohibited by such law, regulation or rule; or
b. limiting or expanding in any way any right the State may otherwise
have to obtain information, documents or testimony from Bayer
pursuant to any applicable state law, regulation or rule, or any right
Bayer may otherwise have to oppose any subpoena, civil
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investigative demand, motion, or other procedure issued, served,
filed, or otherwise employed by the State pursuant to any such
state law, regulation, or rule.

XII.
38.

NOTICES UNDER THIS CONSENT

Any notices that must be sent to the State or to Bayer under this Consent

shall be sent by overnight United States mail. The documents shall be sent to the
following addresses:

For the MSWG:
Suzanne D. Sonnebom
Assistant Attorney General, Consumer Protection Division
G Mennen Williams Building, 6th Floor
525 West Ottawa Street
Post Office Box 30213
Lansing, Michigan 48909
Telephone: 517.335.0855
Facsimile: 517.335.1935
David Anthony Hart
Assistant Attorney General.
1162 Court Street NE
Salem, Oregon 97301-4096
Telephone: 503. 947-4333
Facsimile: 503. 378-5017

For Bayer:
Kristin Graham, Koehler, Esquire
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C. 20005
Telephone: 202.736.8359
Facsimile: 202.736.8711
and
Chief Legal Officer
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205
Telephone: 412.777.5774
Facsimile: 412.777.4417
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FOR BAYER:
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Date:
Maine Bar No. 007211
Downs Rachlin Martin PLLC
P.O. Box 190, 199 Main Street
Burlington, V T 05402-0190
Telephone (802) 863-2375
Facsimile (802) 862-7512
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FOR THE STATE OF M AINE
G. STEVEN ROWE
ATTORNEY GENERAL

Date: January 22, 2007

Christina M. Moylan
Maine Bar No. 7095
Assistant Attorney General
O ffice o f the Attorney General
6 State House Station
Augusta, Maine 04333-0006
Telephone: (207) 626-8838
Facsimile: (207) 624-7730
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i.

IT IS SO ADJUDGED AND ORDERED:
■ rfn

DATED this

day of

2007.

SUPERIOR COURT JUDGE
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SUPERIOR COURT
CIVIL ACTION
DOCKET No. CV-07-21

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE
Pla intiff,
V.

ORDER MODIFYING CONSENT

BAYER CORPORATION

JUDGMENT

Defendant.

This cause coming before the Court on a Joint Motion to M odify the Consent Judgment,
due notice having been given, and the Court being fully advised in the premises,

IT IS HEREBY ORDERED:
1.

The Joint Motion to M odify the Consent Judgment is hereby granted;

2.

The Consent Judgment entered on January 23, 2007, remains in full force and
effect. In addition to the terms contained therein, the Consent Judgment is
modified to add the following terms as set forth below which shall be
incorporated into the Consent Judgment by this reference as though set forth fully
therein:
a.

Section I. Definitions is modified to add Paragraphs X and Y as follows:
l.

Paragraph X. “ Modification Signatory Attorneys General” shall
mean the Attorney General, or his or her designee, o f each o f the
following states that have agreed to this modification o f the
Consent Judgment: Arizona, Arkansas, California, Connecticut,
Delaware, Florida, Idaho, Illinois, Iowa, Kansas, Kentucky, Maine,
Maryland, Massachusetts, Michigan, Mississippi, Montana,

Nevada, North Carolina, Ohio, Oregon, Pennsylvania, South
Dakota, Tennessee, Texas, Washington, and Wisconsin.
ii.

Paragraph Y. “ Y A Z ® ” shall mean the oral contraceptive product
composed o f a combination o f drospirenone and ethinyl estradiol
approved for marketing by FDA pursuant to NDAs 21-676, 21873, and 22-045 under the brand name “ Y A Z ® .”

b.

Section II. Background is modified to add Paragraphs 6 and 7 as follows:
i.

Paragraph 6. Bayer enters into this Modification solely for the
purpose o f resolving the Modification Signatory Attorneys
General’ s investigation under both the Consent Judgment and their
respective states consumer protection statutes into the issues
identified in the Warning Letter issued by FD A ’ s Division o f Drug
Marketing, Advertising, and Communications (“ D D M A C ”) dated
October 3, 2008 (attached as Exhibit 1 and hereafter referred to as
“ Warning Letter”), to avoid unnecessary expense, inconvenience,
and uncertainty without admitting any violation o f the Consent
Judgment or state consumer protection statutes and without
admitting any wrongdoing and for settlement purposes only.

ii.

Paragraph 7. This Modification is made without adjudication o f
any issue o f fact or law or finding o f wrongdoing or liability o f any
kind. It is the intent o f both Bayer and the Modification Attorneys
General that this Modification shall not be admissible in any other
matter or proceeding, and shall not bind Bayer in any respect other
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than in connection with the enforcement o f this Modification.
Except in an action by the Modification Attorneys General to
enforce this Modification, this Modification shall not be construed
or used as a waiver or limitation o f any defense otherwise available
to Bayer or o f Bayer's right to defend itself, or make arguments, in
any other matter related to the issues identified in the Warning
Letter.
c.

In addition to the terms contained in the Consent Judgment, “ Section XIII.
Y A Z ® Advertising” is added with the following Paragraphs:
i.

Bayer shall disseminate corrective advertising that addresses the
issues identified in the Warning Letter, The corrective advertising
campaign shall consist o f a television advertisement and a print
advertisement that have been approved by D D M AC and reviewed
by the Modification Signatory Attorneys General prior to
submission o f this Joint Motion. The television advertisement
shall be broadcast on national cable and network television and the
print advertisement shall be published in magazines with national
distribution. The specific content and timing o f this advertising
campaign shall be as specified and approved by D DM AC and
reviewed by the Modification Signatory Attorneys General prior to
the submission o f this Joint Motion. Bayer shall spend at least $20
million on this corrective advertising campaign. Bayer's
dissemination o f the advertising described in this paragraph shall
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not be construed as an admission by Bayer that the advertisements
identified in the Warning Letter were false, misleading, or
deceptive in any manner. Nor shall Bayer’ s dissemination o f the
advertising described in this paragraph be considered evidence o f
any liability, wrongdoing, or fault by Bayer.
ii.

Bayer agrees to submit all new Direct to Consumer (“ DTC” )
television advertising campaigns for Y A Z ® to FDA for pre
review, wait until Bayer receives a response from FDA prior to
running the advertising campaign, and to modify such advertising
consistent with any final written comments received from FDA.
Non-material modifications to existing advertising campaigns are
not covered by this paragraph.

iii.

Bayer shall not run print advertising for Y A Z suggesting or
marketing Y A Z ® ’ s effectiveness at treating selected symptoms o f
the FDA-approved indication(s) unless the drug’ s specific FDAapproved indication(s) is/are stated as clearly and conspicuously in
the same promotional spread as the symptoms referenced.

iv.

Bayer’ s obligations with respect to paragraphs ii and iii shall
remain in effect for six years following the date this Order
Modifying Consent Judgment is entered by the
court.

v.

Bayer shall submit to each Modification Signatory Attorney
General on the anniversary o f the Effective Date o f this
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Modification a written affirmation setting forth Bayer’ s
compliance with Section XIII.
d.

In addition to the terms contained in the Consent Judgment, Section X IV
RELEASE RE Y A Z ® is added and with the following paragraphs.
i.

Section X IV shall pertain to the product Y A Z ® only and does not
alter or modify the release set forth in Section VII o f the Consent
Judgment.

ii.

Based upon their investigation into Bayer’ s promotional and
marketing practices regarding Y A Z ® and whether those practices
violate the Consent Judgment, the Modification Signatory
Attorneys General have concluded that the Consent Judgment as
modified per this Order Modifying Consent Judgment is the
appropriate resolution o f any alleged violations o f the Consent
Judgment by Bayer regarding its marketing and promotion o f the
product Y A Z ® as described by the Warning Letter attached as
Exhibit 1 and incorporated by this reference as though set forth in
full.

iii.

In Consideration o f the terms set forth in Section XIII, by
execution o f this modification o f Consent Judgment, each
Modification Signatory Attorney General, as defined in Section I,
Paragraph X, releases and forever discharges, to the fullest extent
permitted by law, Bayer and all o f its past and present officers,
directors, shareholders, employees, affiliates, subsidiaries,
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predecessors, assigns and successors (hereinafter referred to
collectively as the “ Released Parties”), from contempt proceedings
that were or could have been asserted against the Released Parties
by the Modification Signatory Attorneys General for the marketing
and promotion o f Y A Z ® by engaging in only the specific conduct
described in the Warning Letter attached hereto as Exhibit 1 and
incorporated by this reference as though set forth in full,
iv.

The Modification Signatory Attorneys General also release and
forever discharge, to the fullest extent permitted by law, the
Released Parties from any other claims or causes o f action under
the following consumer protection statutes: ARIZO N A Consumer Fraud Act, A.R.S. § 44-1521, et seq.; ARKANSAS Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101 et seq.;
CALIFORNIA - Bus. & Prof. Code, § 17200 et seq.;
CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn.
Gen. Stat. § 42- 110a et seq.; DELAW ARE - Delaware Consumer
Fraud Act, 6 Del. C. § 2511, et seq. and Deceptive Trade Practices
Act, 6 Del. C, §2532 et seq.; FLORIDA - Deceptive and Unfair
Trade Practices Act, Fla. Stat. Ch. 501.201 et seq.; IDAHO Consumer Protection Act, Idaho Code § 48-601 et seq.; ILLINOIS
- Consumer Fraud and Deceptive Business Practices Act, 815
ILCS § 505/1 et seq.; IOW A - Iowa Consumer Fraud Act, Iowa
Code Section 714.16; KANSAS - Consumer Protection Act,
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K.S.A. 50-623 et seq.; KENTUCKY - Consumer Protection
Statute, KRS 367.170; MAINE - Unfair Trade Practices Act, 5
M.R.S.A. § 205-A et seq.; M ARYLAN D - Consumer Protection
Act, Md. Code Ann., Com. Law § 13-101 et seq.;
MASSACHUSETTS - Consumer Protection Act, M.G.L. c. 93 A et
seq.; MICHIGAN - Consumer Protection Act, Mich. Comp. Laws
§ 445.901 et seq.; MISSISSIPPI - Consumer Protection Act, Miss.
Code Ann. § 75-24-1 et seq.; M ONTANA - Mont. Code Ann. §
30-14-101 et seq.; N EVAD A - Deceptive Trade Practices Act,
Nevada Revised Statutes 598.0903 et seq.; NORTH CAROLINA Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 75-1.1
et seq.; OHIO - Consumer Sales Practices Act, R.C. 1345.01 et
seq.; OREGON - Unlawful Trade Practices Act, ORS 646.605 et
seq.; PENNSYLVANIA - Unfair Trade Practices and Consumer
Protection Law, 73 P.S. § 201-1 et seq.; SOUTH D AK O TA Deceptive Trade Practices Act, S.D. Codified Laws § 37-24, et
seq.; TENNESSEE - Tennessee Consumer Protection Act, Term.
Code Ann.

§§ 47-18-101 et seq.; TEXAS - Deceptive Trade

Practices - Consumer Protection Act, Tex. Bus. and Com. Code
§ 17.47, et seq.; WASHINGTON - Unfair Business
Practices/Consumer Protection Act, R.C.W. 19.86 et seq.;
WISCONSIN - Wis. Stat. § 100.18 et seq. (Fraudulent
Representations) and Wis. Stat. § 100.182 et seq. (Fraudulent Drug
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Advertising) that were or could have been asserted against the
Released Parties by the Modification Signatory Attorneys General
for the marketing and promotion o f Y A Z ® by engaging in only the
specific conduct described in the Warning Letter attached hereto as
Exhibit 1 and incorporated by this reference as though set forth in
full. This release does not extend to conduct or advertisements by
the Released Parties that were not specifically described in the
Warning Letters attached hereto as Exhibit 1 including, but not
limited to, conduct that occurred prior to or subsequent to the
described conduct, conduct pertaining to advertisements not
addressed in the Warning Letter, or conduct beyond the scope o f
what is described in the Warning Letter.
e.

Notwithstanding any term o f this Modification, specifically reserved and
excluded from the Released Claims as to any entity or person, including
Released Parties, are any and all o f the following:
i.

Any criminal liability that any person or entity, including Released
Parties, has or may have to any or all o f the Modification Signatory
Attorneys General;

ii.

Any civil or administrative liability that any person or entity,
including Released Parties, has or may have to any or all o f the
Modification Signatory Attorneys General, under any statute,
regulation or rule not expressly covered by the release in Paragraph
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iii. above, including, but not limited to, any and all o f the following
claims:
1.

State or federal antitrust violations;

2.

Reporting practices, including "best price", "average
wholesale price" or "wholesale acquisition cost";

3.

Medicaid violations, including federal Medicaid drug
rebate statute violations, Medicaid fraud or abuse, and/or
kickback violations related to any State's Medicaid
program;

4.

State false claims violations; and,

5.

Claims to enforce the terms and conditions o f this
Modification.

iii.

Any liability under the above-cited consumer protection laws o f
any or all o f the Modification Signatory Attorneys General which
any person or entity, including Released Parties, has or may have
to individual consumers or State program payors o f said Individual
States, and which have not been specifically enumerated as
included herein.

3.

The Clerk is ordered to enter this Order Modifying Consent Judgment forthwith.
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APPROVED:
PLAINTIFF, STATE OF MAINE

By:

, VVi
Christina M. Moylan
Assistant Attorney General

Date:
27

10

APPROVED:
DEFENDANT, B A Y E R CORPORATION

Date:
Chief Legal Officer
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205
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Approved as to form :

Date:
Maine Bar No. 007211
DOWNS RACHLIN M ARTIN PLLC
P.O. Box 190,199 Maine Street
Burlington, VT 05402-0190
Telephone: (802) 863-2375
Facsimile: (802)862-7512

Attorneyfo r Bayer Corporation
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SO ORDERED:

Date
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